メタクリル酸＝2,3 - エポキシプロピルのマウスを用いた
吸入によるがん原性試験報告書

試験番号：0795

TABLES

TABLES

TABLES (CONTINUED)

TABLES (CONTINUED)

TABLE A

CONCENTRATIONS OF 2,3-EPOXYPROPYL METHACRYLATE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY

CONCENTRATIONS OF 2,3-EPOXYPROPYL METHACRYLATE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY

Group Name	Concentration(ppm) Mean ± S.D.
Control	0.0 ± 0.0
0.6 ppm	0.6 ± 0.0
2.5 ppm	2.5 ± 0.0
10 ppm	10.1 ± 0.1

TABLE B1

SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
0.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
2.5ppm	50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
10ppm	50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
0.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
2.5ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	48/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	96.0
10ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0
0.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0
2.5ppm	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	47/50	47/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	94.0	94.0
10ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	47/50	47/50	47/50	47/50	47/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	94.0	94.0	94.0	94.0	94.0
0.6ppm	50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	47/50	47/50	46/50	46/50	46/50	46/50
		98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	94.0	94.0	92.0	92.0	92.0	92.0
2.5ppm	50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50
		94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0
10ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50
		94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0
0.6ppm	50	46/50	46/50	46/50	45/50	45/50	45/50	45/50	45/50	44/50	44/50	44/50	44/50	44/50	44/50
		92.0	92.0	92.0	90.0	90.0	90.0	90.0	90.0	88.0	88.0	88.0	88.0	88.0	88.0
2.5ppm	50	46/50	46/50	46/50	45/50	45/50	45/50	45/50	45/50	45/50	44/50	44/50	44/50	42/50	42/50
		92.0	92.0	92.0	90.0	90.0	90.0	90.0	90.0	90.0	88.0	88.0	88.0	84.0	84.0
10ppm	50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	47/50	46/50	46/50	46/50	46/50	46/50
		98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	94.0	92.0	92.0	92.0	92.0	92.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	46/50	46/50	46/50	46/50	44/50	44/50	44/50	44/50	43/50	43/50	42/50	42/50	42/50	41/50
		92.0	92.0	92.0	92.0	88.0	88.0	88.0	88.0	86.0	86.0	84.0	84.0	84.0	82.0
0.6ppm	50	44/50	44/50	44/50	44/50	44/50	44/50	42/50	42/50	42/50	42/50	42/50	41/50	40/50	40/50
		88.0	88.0	88.0	88.0	88.0	88.0	84.0	84.0	84.0	84.0	84.0	82.0	80.0	80.0
2.5ppm	50	42/50	42/50	42/50	42/50	42/50	42/50	41/50	40/50	40/50	38/50	34/50	33/50	32/50	32/50
		84.0	84.0	84.0	84.0	84.0	84.0	82.0	80.0	80.0	76.0	68.0	66.0	64.0	64.0
10ppm	50	45/50	45/50	45/50	44/50	44/50	44/50	44/50	42/50	41/50	40/50	39/50	38/50	37/50	37/50
		90.0	90.0	90.0	88.0	88.0	88.0	88.0	84.0	82.0	80.0	78.0	76.0	74.0	74.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	40/50	37/50	37/50	36/50	36/50	35/50	34/50	34/50	32/50	32/50	31/50	31/50	31/50	29/50
		80.0	74.0	74.0	72.0	72.0	70.0	68.0	68.0	64.0	64.0	62.0	62.0	62.0	58.0
0.6ppm	50	40/50	40/50	40/50	40/50	40/50	40/50	39/50	37/50	37/50	37/50	35/50	34/50	30/50	29/50
		80.0	80.0	80.0	80.0	80.0	80.0	78.0	74.0	74.0	74.0	70.0	68.0	60.0	58.0
2.5ppm	50	32/50	32/50	32/50	31/50	30/50	30/50	28/50	26/50	26/50	24/50	23/50	23/50	23/50	23/50
		64.0	64.0	64.0	62.0	60.0	60.0	56.0	52.0	52.0	48.0	46.0	46.0	46.0	46.0
10ppm	50	35/50	34/50	32/50	31/50	30/50	29/50	26/50	25/50	24/50	22/50	22/50	22/50	21/50	21/50
		70.0	68.0	64.0	62.0	60.0	58.0	52.0	50.0	48.0	44.0	44.0	44.0	42.0	42.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 98	99	100	101	102	103	104	105
Control	50	28/50	28/50	28/50	27/50	27/50	27/50	26/50	26/50
		56.0	56.0	56.0	54.0	54.0	54.0	52.0	52.0
0.6ppm	50	29/50	27/50	26/50	26/50	26/50	26/50	26/50	26/50
		58.0	54.0	52.0	52.0	52.0	52.0	52.0	52.0
2.5ppm	50	22/50	21/50	21/50	21/50	18/50	17/50	16/50	15/50
		44.0	42.0	42.0	42.0	36.0	34.0	32.0	30.0
10ppm	50	20/50	20/50	20/50	17/50	17/50	16/50	14/50	14/50
		40.0	40.0	40.0	34.0	34.0	32.0	28.0	28.0

Number of survival/ Number of effective animals
Survival rate(%)

TABLE B2

SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
0.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
2.5ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
10ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
0.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
2.5ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0
10ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
0.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
2.5ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
10ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
0.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0
2.5ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
10ppm	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	48/50	48/50	48/50	47/50	47/50	46/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	96.0	96.0	96.0	94.0	94.0	92.0
0.6ppm	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	47/50	47/50	46/50	46/50	45/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	94.0	94.0	92.0	92.0	90.0
2.5ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	47/50	47/50	47/50	46/50	46/50	45/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	96.0	94.0	94.0	94.0	92.0	92.0	90.0
10ppm	50	48/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	45/50	45/50	45/50	44/50	43/50	43/50
		96.0	94.0	94.0	94.0	94.0	94.0	94.0	92.0	90.0	90.0	90.0	88.0	86.0	86.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	45/50	45/50	45/50	45/50	45/50	44/50	44/50	43/50	43/50	41/50	40/50	40/50	39/50	38/50
		90.0	90.0	90.0	90.0	90.0	88.0	88.0	86.0	86.0	82.0	80.0	80.0	78.0	76.0
0.6ppm	50	45/50	45/50	45/50	45/50	43/50	43/50	42/50	41/50	41/50	41/50	40/50	40/50	39/50	36/50
		90.0	90.0	90.0	90.0	86.0	86.0	84.0	82.0	82.0	82.0	80.0	80.0	78.0	72.0
2.5ppm	50	45/50	45/50	45/50	45/50	45/50	45/50	44/50	44/50	44/50	44/50	44/50	44/50	44/50	41/50
		90.0	90.0	90.0	90.0	90.0	90.0	88.0	88.0	88.0	88.0	88.0	88.0	88.0	82.0
10ppm	50	43/50	42/50	42/50	40/50	40/50	39/50	39/50	39/50	38/50	38/50	37/50	37/50	37/50	37/50
		86.0	84.0	84.0	80.0	80.0	78.0	78.0	78.0	76.0	76.0	74.0	74.0	74.0	74.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	38/50	38/50	37/50	37/50	36/50	36/50	36/50	36/50	35/50	35/50	31/50	31/50	29/50	29/50
		76.0	76.0	74.0	74.0	72.0	72.0	72.0	72.0	70.0	70.0	62.0	62.0	58.0	58.0
0.6ppm	50	36/50	33/50	31/50	31/50	30/50	28/50	27/50	26/50	25/50	25/50	23/50	23/50	22/50	21/50
		72.0	66.0	62.0	62.0	60.0	56.0	54.0	52.0	50.0	50.0	46.0	46.0	44.0	42.0
2.5ppm	50	40/50	38/50	37/50	35/50	35/50	35/50	33/50	32/50	32/50	30/50	30/50	28/50	28/50	27/50
		80.0	76.0	74.0	70.0	70.0	70.0	66.0	64.0	64.0	60.0	60.0	56.0	56.0	54.0
10ppm	50	36/50	34/50	32/50	31/50	29/50	27/50	26/50	26/50	22/50	20/50	20/50	17/50	17/50	16/50
		72.0	68.0	64.0	62.0	58.0	54.0	52.0	52.0	44.0	40.0	40.0	34.0	34.0	32.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 105
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 98	99	100	101	102	103	104	105
Control	50	29/50	28/50	28/50	28/50	27/50	27/50	27/50	27/50
		58.0	56.0	56.0	56.0	54.0	54.0	54.0	54.0
0.6ppm	50	20/50	19/50	16/50	15/50	15/50	15/50	15/50	15/50
		40.0	38.0	32.0	30.0	30.0	30.0	30.0	30.0
2.5ppm	50	27/50	27/50	27/50	25/50	24/50	22/50	19/50	19/50
		54.0	54.0	54.0	50.0	48.0	44.0	38.0	38.0
10ppm	50	14/50	14/50	12/50	12/50	12/50	9/50	9/50	9/50
		28.0	28.0	24.0	24.0	24.0	18.0	18.0	18.0

Number of survival/ Number of effective animals
Survival rate(%)

TABLE C1

CLINICAL OBSERVATION : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
DEATH	Control	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
DEATH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	2
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
DEATH	Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	0.6ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	2	2	2
	10ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
DEATH	Control	2	2	2	2	2	2	2	2	3	3	3	3	3	3
	0.6ppm	1	1	1	1	2	2	2	3	3	4	4	4	4	4
	2.5ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	3
	10ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	1	1	1	1	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	1	1	1	1	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
DEATH	Control	3	3	3	3	3	3	3	3	3	3	3	3	3	4
	0.6ppm	4	4	5	5	5	5	5	6	6	6	6	6	6	6
	2.5ppm	3	3	4	4	4	4	4	4	5	5	5	7	7	7
	10ppm	1	1	1	1	2	2	2	3	3	3	3	3	3	3
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	2
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	0	0	0	0	0	0	0	2	2	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
DEATH	Control	4	4	4	6	6	6	6	7	7	8	8	8	9	10
	0.6ppm	6	6	6	6	6	8	8	8	8	8	9	9	9	9
	2.5ppm	7	7	7	7	7	8	9	9	10	13	13	13	13	13
	10ppm	3	3	3	3	3	3	5	5	6	7	8	9	9	10
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	2.5ppm	1	1	1	1	1	1	1	1	2	3	4	5	5	5
	10ppm	2	2	3	3	3	3	3	4	4	4	4	4	4	5
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	1	0	0	0	0	0	0	0	1	0	0	0	0	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	1	1	1	1	1	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	1	0	1	1	2
	0.6ppm	0	0	0	0	0	1	1	1	1	1	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
DEATH	Control	13	13	14	14	15	15	15	16	16	17	17	17	19	20
	0.6ppm	9	9	9	9	9	10	11	11	11	12	12	13	13	13
	2.5ppm	13	13	13	13	13	14	15	15	16	16	16	16	16	17
	10ppm	10	10	10	11	12	13	14	14	15	15	15	16	16	17
MORIBUND SACRIFICE	Control	0	0	0	0	0	1	1	2	2	2	2	2	2	2
	0.6ppm	1	1	1	1	1	1	2	2	2	3	4	7	8	8
	2.5ppm	5	5	6	7	7	8	9	9	10	11	11	11	11	11
	10ppm	6	8	9	9	9	11	11	12	13	13	13	13	13	13
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	1	1	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	2	2	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	1	1	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	1	1	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	1	1	1	1	1	0	1	0
	0.6ppm	0	0	0	0	0	0	0	0	0	1	1	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	2
FROG BELLY	Control	1	1	1	1	1	1	1	1	1	1	1	2	1	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	0	1	0	0	0	0	0	0	0	0	1
	10ppm	1	1	1	2	2	1	1	1	0	0	1	1	1	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	1	1	1	0	0	0	0	0
	0.6ppm	0	1	1	1	1	2	1	1	1	1	1	1	2	1
	2.5ppm	0	0	1	3	3	3	2	2	1	0	0	0	0	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
DEATH	Control	20	20	21	21	21	22
	0.6ppm	15	15	15	15	15	15
	2.5ppm	17	17	17	19	20	20
	10ppm	17	17	18	18	19	19
MORIBUND SACRIFICE	Control	2	2	2	2	2	2
	0.6ppm	8	9	9	9	9	9
	2.5ppm	12	12	12	13	13	14
	10ppm	13	13	15	15	15	17
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
SOILED	Control	0	0	1	1	1	0
	0.6ppm	0	0	0	0	1	1
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
PILOERECTION	Control	0	0	1	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	1	1	2	0	0	1
	10ppm	2	2	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	2
	2.5ppm	1	1	1	0	0	0
	10ppm	1	1	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	1	1	1	0
	0.6ppm	0	0	0	0	1	1
	2.5ppm	0	0	0	0	0	0
	10ppm	1	1	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	1	1	1	1	3	4	4
	10ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
INTERNAL MASS	Control	0	0	0	0	1	1	1	1	1	2	2	2	3	3
	0.6ppm	0	0	0	3	3	2	1	2	2	2	2	2	3	3
	2.5ppm	0	0	0	2	2	2	2	2	2	2	3	3	3	3
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	4	4	2	2	2	2	2	2	2	2	2	4	4	4
	10ppm	1	1	0	0	0	0	0	2	1	1	1	0	0	0
INTERNAL MASS	Control	3	3	3	3	3	3	3	3	3	3	3	3	3	2
	0.6ppm	3	3	3	3	4	4	4	4	5	5	5	5	5	5
	2.5ppm	3	5	5	6	7	7	7	7	7	7	7	7	7	7
	10ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	2	3	3	3	3	3	2	2	2	2	2	2	2
	0.6ppm	0	0	0	0	0	1	1	0	0	1	1	2	2	2
	2.5ppm	4	4	4	4	4	4	4	3	3	6	6	0	0	0
	10ppm	0	1	1	1	1	1	2	0	0	0	1	0	0	0
INTERNAL MASS	Control	2	2	2	2	2	2	2	1	1	1	1	1	1	1
	0.6ppm	5	5	5	5	5	5	0	0	0	0	0	0	0	0
	2.5ppm	7	7	7	8	8	8	7	7	7	7	7	6	6	6
	10ppm	1	1	1	1	1	1	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	2	2	2	2	2	3	3	3	3	3	3	6	5	4
	0.6ppm	2	1	1	1	1	1	1	1	1	1	1	3	2	2
	2.5ppm	0	0	1	2	2	3	2	2	2	5	4	4	4	5
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.6ppm	0	0	0	0	0	0	1	1	1	0	0	0	0	0
	2.5ppm	6	6	6	6	6	5	5	5	5	5	5	5	5	5
	10ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	4	4	4	4	4	4	4	2	1	2	2	4	4	3
	0.6ppm	2	2	2	2	2	3	3	2	2	2	2	2	2	2
	2.5ppm	7	5	5	4	4	4	4	4	3	3	3	3	3	3
	10ppm	1	1	1	1	0	0	1	0	0	0	0	0	0	0
INTERNAL MASS	Control	1	2	2	2	2	2	1	1	1	1	1	1	2	2
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	2.5ppm	5	5	4	4	4	4	4	4	4	5	5	4	4	4
	10ppm	0	0	0	0	0	1	1	1	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	1	1	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	6	2	2	1	1	1	1	1	1	3	3	4	3	6
	0.6ppm	5	4	4	3	3	3	3	3	3	3	3	4	4	8
	2.5ppm	3	3	3	3	4	4	5	5	5	5	5	5	6	6
	10ppm	0	0	1	1	1	1	1	2	1	1	0	0	2	2
INTERNAL MASS	Control	2	2	2	2	2	1	1	1	1	1	1	1	1	1
	0.6ppm	1	2	3	2	3	3	1	1	2	2	3	3	3	4
	2.5ppm	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	10ppm	0	0	0	0	0	1	1	1	1	2	2	2	2	1
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	2	2	2	2	2	2	1	1	1	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	4	4	4	4	4	4	4	6	6	5	5	6	3	3
	0.6ppm	8	8	8	8	8	8	7	8	8	8	8	7	7	7
	2.5ppm	7	7	7	11	11	11	10	10	9	9	8	8	7	7
	10ppm	2	2	2	2	2	2	2	2	4	4	4	4	4	4
INTERNAL MASS	Control	1	1	1	2	2	1	2	3	4	4	4	3	3	3
	0.6ppm	5	5	5	5	5	6	7	7	8	7	7	6	6	6
	2.5ppm	4	4	4	3	4	6	4	4	4	4	4	3	3	3
	10ppm	3	3	3	3	2	1	1	1	0	1	1	1	1	1
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	1	1	1	1	1	1	1	1	2	2	2	2	2	2
M.PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
EXOPHTHALMOS	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
EXTERNAL MASS	Control	3	3	3	3	3	2
	0.6ppm	5	5	5	5	5	5
	2.5ppm	7	7	7	6	5	4
	10ppm	3	3	2	2	2	3
INTERNAL MASS	Control	3	3	2	2	2	2
	0.6ppm	5	4	4	4	4	4
	2.5ppm	3	3	4	2	2	2
	10ppm	1	1	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	2	2	1	1	1	1
M.PERI EAR	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	1	1	1	1	2	3	3
	10ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	3	3	1	1	1	1	1	1	1	1	1	3	3	3
	10ppm	1	1	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	2	1	1	1	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	1	2	2	2	2	2	1	1	1	1	1	1	1
	0.6ppm	0	0	0	0	0	1	1	0	0	1	1	2	2	2
	2.5ppm	3	3	3	3	3	3	4	1	1	4	4	0	0	0
	10ppm	0	0	0	0	0	0	1	0	0	0	1	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	2	2	2	2	0	0	0
	10ppm	0	1	1	1	1	1	1	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	1	1	1	1	1	2	2	2	2	2	2	3	3	2
	0.6ppm	2	1	1	1	1	1	1	1	1	1	1	2	1	1
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	1	1	1	1	1	1	1	1	1	1	1	3	2	2
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	2.5ppm	0	0	1	2	2	3	2	2	2	5	4	4	4	4
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	2	2	2	2	2	2	2	0	0	0	0	0	0	0
	0.6ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	1	0	0	0	0	0	0	0
M.GENITALIA	Control	2	2	2	2	2	2	2	2	1	1	1	3	3	3
	0.6ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2.5ppm	6	5	5	4	4	4	4	4	3	3	3	3	3	3
	10ppm	1	1	1	1	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	2.5ppm	0	0	0	0	0	0	1	1	0	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	2	2	2	1	1	1	1	1	1	1	1	2	1	2
	0.6ppm	1	1	1	0	0	0	0	0	0	0	0	1	1	1
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	1	1	1	1	1	1	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	4	0	0	0	0	0	0	0	1	2	2	2	2	4
	0.6ppm	4	3	3	3	3	3	3	3	3	3	3	3	3	7
	2.5ppm	3	3	3	3	4	4	5	5	5	5	5	5	6	6
	10ppm	0	0	0	0	0	0	0	1	1	1	0	0	1	1
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	1	1	2	2	2	2	1	1	1	1	0	0	0	0
	0.6ppm	1	1	2	2	2	2	2	2	2	2	2	1	1	1
	2.5ppm	1	1	0	0	0	0	1	1	1	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	1	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	1	1	1	1	1	1	1	1	1	1	1	1	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	2	2	1	1	1	0	0
	0.6ppm	1	1	1	1	1	1	1	1	1	1	1	1	0	0
	2.5ppm	0	0	0	2	2	2	2	2	3	3	3	3	1	2
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	4	4	4	4	4	4	4	4	4	4	4	5	3	3
	0.6ppm	7	7	7	7	7	7	6	7	7	7	7	6	7	7
	2.5ppm	7	7	7	9	9	9	8	8	7	7	6	6	6	5
	10ppm	1	1	1	1	1	1	1	1	2	2	2	2	2	2
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	1	1	1	1	1	0	0	0
	0.6ppm	1	1	1	1	0	2	0	0	0	1	1	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	2	2
	10ppm	2	2	2	2	2	2	2	2	1	1	1	1	1	1
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	1	1	1	1	1	1	1	1	1	2	2	1	1	1
	2.5ppm	0	0	0	0	0	0	0	0	0	1	3	3	2	2
	10ppm	0	0	1	1	1	0	0	0	0	1	1	1	1	1
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
M.BREAST	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	1	1	1	1	0	0
	10ppm	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	2	2	2	2	2	2
	10ppm	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
M.GENITALIA	Control	3	3	3	3	3	2
	0.6ppm	5	5	5	5	5	5
	2.5ppm	5	5	5	4	3	2
	10ppm	1	1	1	1	1	2
EDEMA	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	1
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
EROSION	Control	0	1	1	2	2	1
	0.6ppm	0	0	0	0	0	1
	2.5ppm	2	2	2	0	0	0
	10ppm	1	1	1	1	1	1
CRUSTA	Control	0	0	0	0	0	0
	0.6ppm	1	0	0	0	0	0
	2.5ppm	2	2	2	0	0	0
	10ppm	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DYSPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL RESPIRA. SOUND	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DYSPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL RESPIRA. SOUND	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DYSPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL RESPIRA. SOUND	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
PROLAPSE OF PENIS	Control	0	0	0	0	1	1	1	1	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DYSPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL RESPIRA. SOUND	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DYSPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL RESPIRA. SOUND	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
PROLAPSE OF PENIS	Control	1	1	1	1	1	1	1	1	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DYSPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	2
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	2	3	3	1	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL RESPIRA. SOUND	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	2.5ppm	1	1	1	1	1	1	1	1	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DYSPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	1	1	1	1	1	1	1	0	1
	0.6ppm	0	0	0	0	0	1	1	1	1	0	0	0	0	0
	2.5ppm	0	0	0	1	2	2	0	1	0	0	1	2	3	3
	10ppm	0	0	0	0	0	1	1	0	1	1	2	4	4	4
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
NOISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	1	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL RESPIRA. SOUND	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	1
	0.6ppm	1	1	1	1	1	1
	2.5ppm	0	0	1	1	1	1
	10ppm	0	0	0	0	0	0
DYSPNEA	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	1	0	0	0	0
IRREGULAR BREATHING	Control	0	0	1	1	1	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	4	3	3	1	1	3
	10ppm	5	4	2	5	4	2
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	2	2	0	0	0	0
NOISY	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	1	1	0	0	0
	10ppm	0	0	0	0	0	0
ABNORMAL RESPIRA. SOUND	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	2	1

TABLE C2

CLINICAL OBSERVATION : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TRAUMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TRAUMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	2
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	0
TRAUMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	1	1	1	1	1	2	2	2
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	1	1	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	1	1	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TRAUMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
DEATH	Control	0	0	0	0	0	0	0	1	1	1	1	1	2	3
	0.6ppm	2	2	2	2	2	2	2	2	3	3	4	4	4	4
	2.5ppm	1	1	1	1	1	1	2	3	3	3	4	4	4	4
	10ppm	2	2	2	2	2	2	3	4	4	4	4	5	5	5
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	1	1	1	2	2	2	2
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	10ppm	1	1	1	1	1	1	1	1	1	1	2	2	2	2
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TRAUMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
DEATH	Control	3	3	3	3	4	4	4	4	4	4	4	5	6	6
	0.6ppm	4	4	4	4	4	5	6	6	6	7	7	8	8	8
	2.5ppm	4	4	4	4	4	4	4	4	4	4	4	4	7	8
	10ppm	6	6	7	7	8	8	8	9	9	9	9	9	9	10
MORIBUND SACRIFICE	Control	2	2	2	2	2	2	3	3	5	6	6	6	6	6
	0.6ppm	1	1	1	3	3	3	3	3	3	3	3	3	6	6
	2.5ppm	1	1	1	1	1	2	2	2	2	2	2	2	2	2
	10ppm	2	2	3	3	3	3	3	3	3	4	4	4	4	4
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TRAUMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	1	1	1	1	1	1	1	1	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	1	1	1	1	0	1	1	0	0
	0.6ppm	0	0	1	0	1	1	0	0	0	0	0	0	1	1
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	2	1	1
	10ppm	1	1	0	0	0	0	0	0	0	0	0	1	3	4
SOILED PERI-GENITALIA	Control	0	1	0	1	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
DEATH	Control	6	6	6	7	7	7	7	8	8	12	12	13	13	13
	0.6ppm	8	10	10	11	13	14	14	15	15	16	16	17	17	18
	2.5ppm	10	11	12	12	12	14	15	15	16	16	18	18	18	18
	10ppm	12	13	14	15	17	18	18	19	20	20	21	21	22	23
MORIBUND SACRIFICE	Control	6	6	7	7	7	7	7	7	7	7	7	8	8	8
	0.6ppm	9	9	9	9	9	9	10	10	10	11	11	11	12	12
	2.5ppm	2	2	3	3	3	3	3	3	4	4	4	4	5	5
	10ppm	4	5	5	6	6	6	6	9	10	10	12	12	12	13
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	1	1	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
PILOERECTION	Control	0	0	0	0	0	0	0	1	1	1	1	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TRAUMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	1	0	0	1	1	0	0	0	0	0	0	0
	0.6ppm	1	1	1	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	0	0	0	0	0	0	0	0	1	0	0	0	0
	10ppm	2	2	1	1	0	0	0	2	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
DEATH	Control	14	14	14	15	15	15
	0.6ppm	18	20	21	21	21	21
	2.5ppm	18	18	20	21	22	23
	10ppm	23	23	23	23	26	26
MORIBUND SACRIFICE	Control	8	8	8	8	8	8
	0.6ppm	13	14	14	14	14	14
	2.5ppm	5	5	5	5	6	8
	10ppm	13	15	15	15	15	15
HUNCHBACK POSITION	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	1	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	1
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
TRAUMA	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
FROG BELLY	Control	0	0	2	2	2	2
	0.6ppm	0	0	0	0	0	1
	2.5ppm	0	1	1	1	1	0
	10ppm	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	1	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	2.5ppm	0	0	0	1	1	1	1	1	1	1	1	1	1	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	1	1	0	0
INTERNAL MASS	Control	1	1	1	1	1	1	1	1	2	2	2	3	3	3
	0.6ppm	1	1	1	1	1	2	3	3	3	4	4	0	0	0
	2.5ppm	0	1	1	1	1	1	1	1	1	1	1	2	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	3	3	3	3	3	3	1	0	0	0	0	0	0	1
	0.6ppm	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	2.5ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	10ppm	0	0	0	0	0	0	3	3	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	1	1	1	1	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	3	3	3
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	2	2	2	2	2	1	1	1	0	1	2	2	2	2
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	1	1	1	1	1	1	0	1	1	2	2	2	2	2
INTERNAL MASS	Control	3	3	3	3	3	3	2	1	1	1	1	1	1	1
	0.6ppm	1	1	1	1	1	1	1	1	0	0	0	3	2	2
	2.5ppm	2	2	2	3	3	3	2	1	1	1	0	0	0	0
	10ppm	0	0	0	0	1	1	1	0	0	1	0	0	0	1
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	1	1	1	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	1	2	1	2	2	2	2	1	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	1	1	1	1	1	1	1	1	1	2	2	2	2	1
INTERNAL MASS	Control	1	1	2	2	3	3	2	2	0	0	1	1	1	1
	0.6ppm	2	2	2	1	1	1	2	3	4	4	4	4	6	6
	2.5ppm	0	0	0	0	1	1	1	1	1	3	3	3	3	2
	10ppm	2	3	2	2	2	2	2	1	1	4	5	5	6	6
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	1	1	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	1	2	2	2	2	2	1	1	0	0	0
	0.6ppm	0	0	0	0	1	1	1	1	2	1	1	1	2	1
	2.5ppm	1	0	0	0	0	0	0	0	1	3	3	3	4	4
	10ppm	0	0	1	0	1	3	3	2	2	2	2	2	2	2
INTERNAL MASS	Control	1	1	2	1	1	2	4	6	6	5	5	3	3	4
	0.6ppm	4	3	3	2	1	1	5	5	5	6	6	5	4	4
	2.5ppm	1	1	1	2	2	2	1	1	2	2	0	0	0	1
	10ppm	5	5	4	7	6	6	6	4	4	5	2	2	2	2
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	1	1	1	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
EXOPHTHALMOS	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0
	0.6ppm	0	1	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	1	1	1
	0.6ppm	1	2	1	1	2	2
	2.5ppm	4	4	2	2	2	2
	10ppm	2	1	2	2	1	1
INTERNAL MASS	Control	3	3	5	4	4	4
	0.6ppm	4	3	3	3	3	4
	2.5ppm	2	2	3	3	2	2
	10ppm	3	1	1	1	0	1
M.EYE	Control	0	0	0	0	0	0
	0.6ppm	0	1	0	0	0	0
	2.5ppm	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	1	1	0	0	0	0
	10ppm	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	1	0	0	0	0
	10ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	1	1	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	1	1	1	1	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	1	1	1	1	1	1	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	1	1	1	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	1	1	1	1	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	1	1	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	1	1	1	1	1	1	1	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	0
M.ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	1	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	1	1	1	1	1	0	0	0	0	0
	0.6ppm	0	0	0	0	1	1	1	1	1	0	0	0	1	1
	2.5ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	10ppm	0	0	0	0	0	2	2	2	2	2	1	1	1	1
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	1	1	1	1	1	1	1	1	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
M.ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	1	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
M. BREAST	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	1	1	0	0	0	0
	10ppm	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	1	1	1
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	1	1
	2.5ppm	0	1	0	0	0	0
	10ppm	0	0	1	1	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0
	0.6ppm	1	1	1	1	1	1
	2.5ppm	1	1	0	0	0	0
	10ppm	1	1	1	1	1	1
M. HINDLIMB	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	1	0	0	0	0	0
M. ANUS	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	1	1	1	1	1	1	1	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	1	1	1	0	0	0	0	0	1	1	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	2.5ppm	0	0	0	0	0	1	0	0	0	0	0	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	1	1	1	1	1	1	1	1	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	1	0	0	0	0	0	0	1	1	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	0	1
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	1	0	2
	10ppm	0	0	0	0	0	0	0	0	1	0	0	0	1	2
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	1	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	0	0	0	0	0	0	1	1	1	1	1	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	1	1	1	1	1	0	1	1	1	1	1	1	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	1	1	0	0	0	1	1	0	1	1	1	0	0	0
	0.6ppm	0	0	0	0	0	1	1	0	1	1	1	1	1	1
	2.5ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	10ppm	1	1	2	1	0	0	2	0	1	2	2	2	2	1
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0	0	0	0	2	1	1	1	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
EROSION	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0
	0.6ppm	1	0	0	0	0	0
	2.5ppm	1	1	0	0	0	0
	10ppm	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	1
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	1	0	0	1
	0.6ppm	1	1	0	0	0	0
	2.5ppm	0	1	0	0	0	0
	10ppm	1	1	1	2	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0
	0.6ppm	0	0	0	0	0	0
	2.5ppm	0	0	0	0	0	0
	10ppm	0	0	0	0	0	0

TABLE D1

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control Av.Wt.	Control No.of Surviv. <50>	0.6ppm Av.Wt.	0.6ppm % of cont. <50>	0.6ppm No.of Surviv.	2.5ppm Av.Wt.	2.5ppm % of cont. <50>	2.5ppm No.of Surviv.	10ppm Av.Wt.	10ppm % of cont. <50>	10ppm No.of Surviv.
0	24.6 (50)	50/50	24.6 (50)	100	50/50	24.6 (50)	100	50/50	24.6 (50)	100	50/50
1	25.8 (50)	50/50	25.6 (50)	99	50/50	26.0 (50)	101	50/50	25.3 (50)	98	50/50
2	26.5 (50)	50/50	26.1 (50)	98	50/50	26.7 (50)	101	50/50	25.9 (49)	98	49/50
3	27.0 (49)	49/50	26.8 (50)	99	50/50	27.3 (49)	101	49/50	26.5 (49)	98	49/50
4	27.4 (49)	49/50	27.2 (50)	99	50/50	27.7 (49)	101	49/50	27.0 (49)	99	49/50
5	27.9 (49)	49/50	27.6 (50)	99	50/50	28.3 (49)	101	49/50	27.1 (49)	97	49/50
6	28.4 (49)	49/50	28.0 (50)	99	50/50	29.0 (49)	102	49/50	27.4 (49)	96	49/50
7	29.1 (49)	49/50	28.5 (50)	98	50/50	29.4 (49)	101	49/50	28.0 (49)	96	49/50
8	29.5 (49)	49/50	28.8 (50)	98	50/50	30.0 (49)	102	49/50	28.5 (49)	97	49/50
9	30.0 (49)	49/50	29.4 (50)	98	50/50	30.5 (49)	102	49/50	29.0 (49)	97	49/50
10	30.3 (49)	49/50	29.8 (50)	98	50/50	31.1 (49)	103	49/50	29.3 (49)	97	49/50
11	31.4 (49)	49/50	30.3 (50)	96	50/50	32.0 (49)	102	49/50	29.8 (49)	95	49/50
12	31.8 (49)	49/50	30.6 (50)	96	50/50	32.4 (49)	102	49/50	30.3 (49)	95	49/50
13	32.6 (49)	49/50	31.6 (50)	97	50/50	33.2 (49)	102	49/50	31.0 (49)	95	49/50
14	33.0 (49)	49/50	32.2 (50)	98	50/50	33.9 (49)	103	49/50	31.5 (49)	95	49/50
18	35.4 (49)	49/50	34.5 (50)	97	50/50	36.3 (49)	103	49/50	33.9 (49)	96	49/50
22	37.5 (49)	49/50	36.6 (50)	98	50/50	38.5 (49)	103	49/50	35.7 (49)	95	49/50
26	39.8 (49)	49/50	38.4 (50)	96	50/50	40.4 (49)	102	49/50	37.6 (49)	94	49/50
30	41.4 (48)	48/50	39.8 (50)	96	50/50	41.9 (48)	101	48/50	38.6 (49)	93	49/50
34	42.3 (48)	48/50	40.8 (50)	96	50/50	43.0 (48)	102	48/50	39.9 (49)	94	49/50
38	43.0 (48)	48/50	42.0 (50)	98	50/50	43.8 (48)	102	48/50	40.5 (49)	94	49/50
42	43.0 (48)	48/50	42.1 (49)	98	49/50	43.9 (47)	102	47/50	40.6 (49)	94	49/50
46	43.0 (48)	48/50	42.5 (49)	99	49/50	44.5 (47)	103	47/50	41.6 (49)	97	49/50
50	43.4 (48)	48/50	42.6 (47)	98	47/50	44.9 (47)	103	47/50	40.8 (49)	94	49/50
54	43.7 (47)	47/50	43.6 (46)	100	46/50	45.1 (47)	103	47/50	41.1 (49)	94	49/50
58	43.2 (47)	47/50	43.4 (46)	100	46/50	45.3 (46)	105	46/50	40.9 (49)	95	49/50
62	43.1 (47)	47/50	43.8 (45)	102	45/50	44.2 (45)	103	45/50	41.0 (48)	95	48/50
66	43.6 (47)	47/50	43.8 (44)	100	44/50	44.3 (44)	102	44/50	40.9 (46)	94	46/50
70	43.2 (46)	46/50	42.9 (44)	99	44/50	44.3 (42)	103	42/50	40.8 (45)	94	45/50
74	43.0 (44)	44/50	41.4 (44)	96	44/50	42.4 (42)	99	42/50	39.3 (44)	91	44/50
78	42.5 (43)	43/50	42.0 (42)	99	42/50	42.1 (40)	99	40/50	39.1 (41)	92	41/50
82	42.0 (42)	42/50	42.3 (40)	101	40/50	43.7 (32)	104	32/50	39.0 (37)	93	37/50
86	41.9 (37)	37/50	40.3 (40)	96	40/50	40.4 (32)	96	32/50	37.6 (32)	90	32/50
90	41.7 (34)	34/50	39.9 (39)	96	39/50	39.1 (28)	94	28/50	39.3 (26)	94	26/50
94	40.2 (31)	31/50	39.0 (35)	97	35/50	38.7 (23)	96	23/50	38.7 (22)	96	22/50
98	38.6 (28)	28/50	39.1 (29)	101	29/50	37.4 (22)	97	22/50	36.6 (20)	95	20/50
102	36.8 (27)	27/50	37.5 (26)	102	26/50	36.1 (18)	98	18/50	35.8 (17)	97	17/50
104	37.6 (26)	26/50	37.8 (26)	101	26/50	35.2 (16)	94	16/50	36.3 (14)	97	14/50

< >:No.of effective animals, ( ):No.of measured animals Av.Wt. : g

TABLE D2

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control Av.Wt.	Control No.of Surviv. <50>	0.6ppm Av.Wt.	0.6ppm % of cont. <50>	0.6ppm No.of Surviv.	2.5ppm Av.Wt.	2.5ppm % of cont. <50>	2.5ppm No.of Surviv.	10ppm Av.Wt.	10ppm % of cont. <50>	10ppm No.of Surviv.
0	19.8 (50)	50/50	19.8 (50)	100	50/50	19.8 (50)	100	50/50	19.8 (50)	100	50/50
1	20.3 (50)	50/50	20.1 (50)	99	50/50	20.4 (50)	100	50/50	20.2 (50)	100	50/50
2	20.9 (50)	50/50	20.6 (50)	99	50/50	20.8 (50)	100	50/50	20.5 (50)	98	50/50
3	21.5 (50)	50/50	21.3 (50)	99	50/50	21.3 (50)	99	50/50	20.8 (50)	97	50/50
4	22.1 (50)	50/50	21.6 (50)	98	50/50	21.7 (50)	98	50/50	21.5 (50)	97	50/50
5	22.9 (50)	50/50	22.0 (50)	96	50/50	22.6 (50)	99	50/50	21.9 (50)	96	50/50
6	23.5 (50)	50/50	22.6 (50)	96	50/50	22.9 (50)	97	50/50	22.2 (50)	94	50/50
7	24.2 (50)	50/50	23.3 (50)	96	50/50	23.5 (50)	97	50/50	22.9 (50)	95	50/50
8	24.1 (50)	50/50	23.3 (50)	97	50/50	23.7 (50)	98	50/50	23.2 (50)	96	50/50
9	24.2 (50)	50/50	23.5 (50)	97	50/50	23.8 (50)	98	50/50	23.4 (50)	97	50/50
10	24.4 (50)	50/50	23.8 (50)	98	50/50	24.1 (50)	99	50/50	23.9 (50)	98	50/50
11	24.9 (50)	50/50	24.3 (50)	98	50/50	24.6 (50)	99	50/50	24.2 (50)	97	50/50
12	25.1 (50)	50/50	24.4 (50)	97	50/50	24.6 (50)	98	50/50	24.2 (50)	96	50/50
13	25.6 (50)	50/50	24.8 (50)	97	50/50	24.9 (50)	97	50/50	24.7 (50)	96	50/50
14	25.7 (50)	50/50	24.9 (50)	97	50/50	25.4 (50)	99	50/50	24.8 (50)	96	50/50
18	26.7 (50)	50/50	26.0 (50)	97	50/50	26.2 (50)	98	50/50	25.9 (50)	97	50/50
22	27.4 (50)	50/50	27.1 (50)	99	50/50	26.9 (49)	98	49/50	26.6 (50)	97	50/50
26	28.0 (50)	50/50	27.7 (50)	99	50/50	27.3 (49)	98	49/50	27.0 (50)	96	50/50
30	28.5 (50)	50/50	28.4 (50)	100	50/50	28.2 (49)	99	49/50	27.8 (49)	98	49/50
34	29.4 (50)	50/50	28.9 (50)	98	50/50	28.7 (49)	98	49/50	28.6 (49)	97	49/50
38	29.3 (50)	50/50	29.4 (50)	100	50/50	28.8 (49)	98	49/50	28.2 (49)	96	49/50
42	29.8 (50)	50/50	29.6 (50)	99	50/50	29.2 (49)	98	49/50	29.1 (48)	98	48/50
46	29.5 (50)	50/50	30.3 (50)	103	50/50	29.4 (49)	100	49/50	29.2 (48)	99	48/50
50	30.0 (50)	50/50	29.9 (49)	100	49/50	29.7 (49)	99	49/50	28.9 (48)	96	48/50
54	30.4 (50)	50/50	30.5 (48)	100	48/50	30.2 (49)	99	49/50	29.5 (48)	97	48/50
58	30.3 (50)	50/50	30.2 (48)	100	48/50	30.5 (49)	101	49/50	29.8 (47)	98	47/50
62	30.5 (50)	50/50	31.3 (48)	103	48/50	31.2 (49)	102	49/50	30.2 (47)	99	47/50
66	31.1 (48)	48/50	31.3 (47)	101	47/50	31.2 (47)	100	47/50	30.3 (45)	97	45/50
70	31.1 (45)	45/50	30.9 (45)	99	45/50	31.1 (45)	100	45/50	30.7 (43)	99	43/50
74	31.3 (45)	45/50	31.0 (43)	99	43/50	31.2 (45)	100	45/50	30.2 (40)	96	40/50
78	31.6 (43)	43/50	31.6 (41)	100	41/50	31.7 (44)	100	44/50	30.1 (38)	95	38/50
82	31.5 (39)	39/50	31.8 (39)	101	39/50	31.7 (44)	101	44/50	30.9 (37)	98	37/50
86	31.3 (37)	37/50	31.7 (31)	101	31/50	31.5 (37)	101	37/50	30.6 (32)	98	32/50
90	31.6 (36)	36/50	31.5 (27)	100	27/50	31.6 (33)	100	33/50	30.9 (26)	98	26/50
94	30.8 (31)	31/50	31.6 (23)	103	23/50	31.9 (30)	104	30/50	30.0 (20)	97	20/50
98	31.2 (29)	29/50	31.1 (20)	100	20/50	32.4 (27)	104	27/50	30.5 (14)	98	14/50
102	30.7 (27)	27/50	32.5 (15)	106	15/50	33.1 (24)	108	24/50	29.9 (12)	97	12/50
104	31.2 (27)	27/50	33.8 (15)	108	15/50	32.4 (19)	104	19/50	30.2 (9)	97	9/50

< >:No.of effective animals, ( ):No.of measured animals Av.Wt. : g

TABLE D3

BODY WEIGHT CHANGES : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 0	1	2	3	4	5	6
Control	24.6± 0.8	25.8± 0.9	26.5± 1.2	27.0± 1.1	27.4± 1.2	27.9± 1.2	28.4± 1.2
0.6ppm	24.6± 0.8	25.6± 1.0	26.1± 1.1	26.8± 1.3	27.2± 1.3	27.6± 1.5	28.0± 1.5
2.5ppm	24.6± 0.8	26.0± 1.1	26.7± 1.1	27.3± 1.1	27.7± 1.2	28.3± 1.3	29.0± 1.4
10ppm	24.6± 0.8	25.3± 1.0*	25.9± 0.9*	26.5± 1.0	27.0± 1.0	27.1± 1.2*	27.4± 1.2**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 7	8	9	10	11	12	13
Control	29.1± 1.4	29.5± 1.6	30.0± 1.6	30.3± 1.6	31.4± 1.8	31.8± 2.0	32.6± 2.0
0.6ppm	28.5± 1.6	28.8± 1.7	29.4± 1.9	29.8± 2.0	30.3± 2.1*	30.6± 2.2*	31.6± 2.4
2.5ppm	29.4± 1.6	30.0± 1.8	30.5± 1.9	31.1± 2.1	32.0± 2.3	32.4± 2.4	33.2± 2.4
10ppm	28.0± 1.3**	28.5± 1.4*	29.0± 1.7**	29.3± 1.7*	29.8± 1.9**	30.3± 2.0**	31.0± 2.1**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 14	18	22	26	30	34	38
Control	33.0± 2.1	35.4± 2.4	37.5± 2.8	39.8± 3.2	41.4± 3.5	42.3± 3.8	43.0± 4.0
0.6ppm	32.2± 2.5	34.5± 3.0	36.6± 3.5	38.4± 3.9	39.8± 4.4	40.8± 4.8	42.0± 5.5
2.5ppm	33.9± 2.6	36.3± 3.0	38.5± 3.6	40.4± 4.1	41.9± 4.6	43.0± 4.7	43.8± 4.8
10ppm	31.5± 2.2**	33.9± 2.7*	35.7± 3.2*	37.6± 3.7**	38.6± 4.3**	39.9± 4.2*	40.5± 4.2*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 42	46	50	54	58	62	66
Control	43.0± 4.1	43.0± 4.8	43.4± 4.9	43.7± 5.1	43.2± 6.1	43.1± 6.5	43.6± 6.8
0.6ppm	42.1± 5.1	42.5± 5.4	42.6± 5.6	43.6± 5.6	43.4± 5.8	43.8± 6.1	43.8± 6.5
2.5ppm	43.9± 5.2	44.5± 5.1	44.9± 5.7	45.1± 6.0	45.3± 6.6	44.2± 7.2	44.3± 7.1
10ppm	40.6± 4.2*	41.6± 4.6	40.8± 4.6*	41.1± 5.5	40.9± 5.7	41.0± 5.8	40.9± 5.8

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 70	74	78	82	86	90	94
Control	43.2± 7.7	43.0± 7.2	42.5± 7.7	42.0± 8.1	41.9± 7.7	41.7± 6.4	40.2± 6.0
0.6ppm	42.9± 7.0	41.4± 7.4	42.0± 7.5	42.3± 7.4	40.3± 7.0	39.9± 6.8	39.0± 6.7
2.5ppm	44.3± 7.8	42.4± 8.9	42.1± 9.2	43.7± 7.6	40.4± 6.7	39.1± 6.2	38.7± 5.0
10ppm	40.8± 6.6	39.3± 7.2	39.1± 7.3	39.0± 7.7	37.6± 8.3	39.3± 6.7	38.7± 6.4

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 98	102	104
Control	38.6± 5.2	36.8± 5.0	37.6± 4.6
0.6ppm	39.1± 6.6	37.5± 6.1	37.8± 6.2
2.5ppm	37.4± 5.3	36.1± 5.3	35.2± 5.7
10ppm	36.6± 6.7	35.8± 5.9	36.3± 5.9

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE D4

BODY WEIGHT CHANGES : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 0	1	2	3	4	5	6
Control	19.8± 0.8	20.3± 0.8	20.9± 0.9	21.5± 0.9	22.1± 0.9	22.9± 1.0	23.5± 0.9
0.6ppm	19.8± 0.8	20.1± 0.9	20.6± 1.0	21.3± 1.0	21.6± 0.9**	22.0± 1.0**	22.6± 1.0**
2.5ppm	19.8± 0.8	20.4± 0.9	20.8± 0.9	21.3± 0.9	21.7± 0.9	22.6± 1.1	22.9± 1.1*
10ppm	19.8± 0.8	20.2± 0.8	20.5± 0.9	20.8± 0.9**	21.5± 0.9**	21.9± 1.0**	22.2± 1.2**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 7	8	9	10	11	12	13
Control	24.2± 1.1	24.1± 1.1	24.2± 0.9	24.4± 1.1	24.9± 1.0	25.1± 1.2	25.6± 1.1
0.6ppm	23.3± 1.2**	23.3± 1.1**	23.5± 1.2**	23.8± 1.0**	24.3± 1.2*	24.4± 1.3*	24.8± 1.2**
2.5ppm	23.5± 1.0**	23.7± 1.0	23.8± 1.1	24.1± 1.0	24.6± 1.1	24.6± 1.1	24.9± 1.2*
10ppm	22.9± 1.1**	23.2± 1.0**	23.4± 0.9**	23.9± 1.0	24.2± 1.3**	24.2± 1.2**	24.7± 1.2**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 14	18	22	26	30	34	38
Control	25.7± 1.4	26.7± 1.8	27.4± 1.8	28.0± 2.0	28.5± 2.1	29.4± 2.3	29.3± 1.8
0.6ppm	24.9± 1.3**	26.0± 1.6	27.1± 1.9	27.7± 2.2	28.4± 2.6	28.9± 2.8	29.4± 2.5
2.5ppm	25.4± 1.2	26.2± 1.3	26.9± 1.5	27.3± 1.6	28.2± 1.7	28.7± 1.7	28.8± 1.7
10ppm	24.8± 1.3**	25.9± 1.7	26.6± 1.9	27.0± 1.7	27.8± 2.1	28.6± 1.9	28.2± 1.9**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 42	46	50	54	58	62	66
Control	29.8± 1.9	29.5± 2.0	30.0± 2.2	30.4± 2.2	30.3± 2.2	30.5± 2.0	31.1± 2.2
0.6ppm	29.6± 2.7	30.3± 2.7	29.9± 3.1	30.5± 3.0	30.2± 3.2	31.3± 3.2	31.3± 3.2
2.5ppm	29.2± 1.7	29.4± 1.7	29.7± 1.7	30.2± 2.2	30.5± 1.7	31.2± 3.0	31.2± 2.5
10ppm	29.1± 1.6	29.2± 1.9	28.9± 1.9	29.5± 2.0	29.8± 2.0	30.2± 2.6	30.3± 2.2

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 70	74	78	82	86	90	94
Control	31.1± 2.1	31.3± 2.1	31.6± 2.3	31.5± 2.1	31.3± 2.4	31.6± 2.9	30.8± 2.7
0.6ppm	30.9± 2.8	31.0± 3.0	31.6± 3.2	31.8± 3.4	31.7± 3.8	31.5± 2.7	31.6± 2.6
2.5ppm	31.1± 2.3	31.2± 2.4	31.7± 2.6	31.7± 2.9	31.5± 2.8	31.6± 3.0	31.9± 3.3
10ppm	30.7± 2.3	30.2± 2.9	30.1± 2.8*	30.9± 3.1	30.6± 3.7	30.9± 2.9	30.0± 2.7

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 98	102	104
Control	31.2± 2.9	30.7± 3.5	31.2± 3.8
0.6ppm	31.1± 3.4	32.5± 2.5	33.8± 2.8
2.5ppm	32.4± 3.1	33.1± 4.6	32.4± 4.2
10ppm	30.5± 2.5	29.9± 3.7	30.2± 3.6

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE E1

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week-Day on Study	Control Av.FC.	Control No. of Surviv. <50>	0.6ppm Av.FC.	0.6ppm % of cont. <50>	0.6ppm No. of Surviv.	2.5ppm Av.FC.	2.5ppm % of cont. <50>	2.5ppm No. of Surviv.	10ppm Av.FC.	10ppm % of cont. <50>	10ppm No. of Surviv.
1-7	4.3 (50)	50/50	4.2 (50)	98	50/50	4.2 (50)	98	50/50	4.1 (50)	95	50/50
2-7	4.2 (50)	50/50	4.1 (50)	98	50/50	4.3 (50)	102	50/50	4.1 (49)	98	49/50
3-7	4.3 (49)	49/50	4.3 (50)	100	50/50	4.4 (49)	102	49/50	4.2 (49)	98	49/50
4-7	4.3 (49)	49/50	4.3 (50)	100	50/50	4.5 (49)	105	49/50	4.2 (49)	98	49/50
5-7	4.4 (49)	49/50	4.3 (50)	98	50/50	4.6 (49)	105	49/50	4.2 (49)	95	49/50
6-7	4.4 (49)	49/50	4.4 (50)	100	50/50	4.5 (49)	102	49/50	4.3 (49)	98	49/50
7-7	4.4 (49)	49/50	4.3 (50)	98	50/50	4.5 (49)	102	49/50	4.3 (49)	98	49/50
8-7	4.5 (49)	49/50	4.4 (50)	98	50/50	4.6 (49)	102	49/50	4.4 (49)	98	49/50
9-7	4.5 (49)	49/50	4.4 (50)	98	50/50	4.6 (49)	102	49/50	4.4 (49)	98	49/50
10-7	4.6 (49)	49/50	4.5 (50)	98	50/50	4.7 (49)	102	49/50	4.4 (49)	96	49/50
11-7	4.5 (49)	49/50	4.4 (50)	98	50/50	4.7 (49)	104	49/50	4.4 (49)	98	49/50
12-7	4.6 (49)	49/50	4.5 (50)	98	50/50	4.7 (49)	102	49/50	4.5 (49)	98	49/50
13-7	4.7 (49)	49/50	4.6 (50)	98	50/50	4.7 (49)	100	49/50	4.5 (49)	96	49/50
14-7	4.6 (49)	49/50	4.6 (50)	100	50/50	4.7 (49)	102	49/50	4.5 (49)	98	49/50
18-7	4.8 (49)	49/50	4.7 (50)	98	50/50	4.8 (49)	100	49/50	4.6 (49)	96	49/50
22-7	4.7 (49)	49/50	4.6 (50)	98	50/50	4.7 (49)	100	49/50	4.5 (49)	96	49/50
26-7	4.9 (49)	49/50	4.8 (50)	98	50/50	4.8 (49)	98	49/50	4.7 (49)	96	49/50
30-7	4.8 (48)	48/50	4.7 (50)	98	50/50	4.6 (48)	96	48/50	4.6 (49)	96	49/50
34-7	4.8 (48)	48/50	4.7 (50)	98	50/50	4.7 (48)	98	48/50	4.5 (49)	94	49/50
38-7	4.6 (48)	48/50	4.6 (50)	100	50/50	4.7 (48)	102	48/50	4.5 (49)	98	49/50
42-7	4.6 (48)	48/50	4.7 (49)	102	49/50	4.7 (47)	102	47/50	4.5 (49)	98	49/50
46-7	4.9 (48)	48/50	4.8 (49)	98	49/50	5.0 (47)	102	47/50	4.8 (49)	98	49/50
50-7	4.8 (48)	48/50	4.8 (47)	100	47/50	4.9 (47)	102	47/50	4.6 (49)	96	49/50
54-7	4.9 (47)	47/50	4.9 (46)	100	46/50	5.0 (47)	102	47/50	4.7 (49)	96	49/50
58-7	4.9 (47)	47/50	4.9 (46)	100	46/50	4.9 (46)	100	46/50	4.6 (49)	94	49/50
62-7	4.8 (47)	47/50	4.8 (45)	100	45/50	4.8 (45)	100	45/50	4.6 (48)	96	48/50
66-7	4.8 (47)	47/50	4.8 (44)	100	44/50	4.8 (44)	100	44/50	4.5 (46)	94	46/50
70-7	4.7 (46)	46/50	4.7 (44)	100	44/50	4.9 (42)	104	42/50	4.6 (45)	98	45/50
74-7	4.7 (44)	44/50	4.7 (44)	100	44/50	4.6 (42)	98	42/50	4.3 (44)	91	44/50
78-7	5.0 (43)	43/50	4.8 (42)	96	42/50	4.9 (40)	98	40/50	4.5 (41)	90	41/50
82-7	4.8 (42)	42/50	4.7 (40)	98	40/50	4.8 (32)	100	32/50	4.5 (37)	94	37/50
86-7	4.7 (37)	37/50	4.7 (40)	100	40/50	4.7 (32)	100	32/50	4.5 (32)	96	32/50
90-7	4.8 (34)	34/50	4.9 (39)	102	39/50	4.9 (28)	102	28/50	4.6 (26)	96	26/50
94-7	5.0 (31)	31/50	4.8 (35)	96	35/50	5.0 (23)	100	23/50	4.5 (22)	90	22/50
98-7	5.1 (28)	28/50	5.0 (29)	98	29/50	5.0 (22)	98	22/50	4.4 (20)	86	20/50
102-7	5.0 (27)	27/50	4.8 (26)	96	26/50	4.8 (18)	96	18/50	4.4 (17)	88	17/50
104-7	5.3 (26)	26/50	5.1 (26)	96	26/50	5.1 (16)	96	16/50	4.6 (14)	87	14/50

< >:No.of effective animals, ( ):No.of measured animals Av.FC. : g

TABLE E2

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week-Day on Study	Control Av.FC.	Control No. of Surviv. <50>	0.6ppm Av.FC.	0.6ppm % of cont. <50>	0.6ppm No. of Surviv.	2.5ppm Av.FC.	2.5ppm % of cont. <50>	2.5ppm No. of Surviv.	10ppm Av.FC.	10ppm % of cont. <50>	10ppm No. of Surviv.
1-7	3.6 (50)	50/50	3.5 (50)	97	50/50	3.5 (50)	97	50/50	3.5 (50)	97	50/50
2-7	3.7 (50)	50/50	3.6 (50)	97	50/50	3.5 (50)	95	50/50	3.5 (50)	95	50/50
3-7	4.1 (50)	50/50	3.9 (50)	95	50/50	3.9 (50)	95	50/50	3.8 (50)	93	50/50
4-7	4.3 (50)	50/50	4.0 (50)	93	50/50	4.1 (50)	95	50/50	4.0 (50)	93	50/50
5-7	4.4 (50)	50/50	4.2 (50)	95	50/50	4.2 (50)	95	50/50	4.1 (50)	93	50/50
6-7	4.7 (50)	50/50	4.4 (50)	94	50/50	4.3 (50)	91	50/50	4.1 (49)	87	50/50
7-7	4.6 (49)	50/50	4.4 (50)	96	50/50	4.4 (50)	96	50/50	4.3 (49)	93	50/50
8-7	4.7 (49)	50/50	4.6 (50)	98	50/50	4.6 (50)	98	50/50	4.4 (49)	94	50/50
9-7	4.7 (50)	50/50	4.6 (50)	98	50/50	4.5 (50)	96	50/50	4.4 (49)	94	50/50
10-7	4.7 (50)	50/50	4.6 (50)	98	50/50	4.5 (50)	96	50/50	4.5 (49)	96	50/50
11-7	4.6 (50)	50/50	4.5 (49)	98	50/50	4.5 (50)	98	50/50	4.6 (50)	100	50/50
12-7	4.6 (49)	50/50	4.5 (49)	98	50/50	4.5 (50)	98	50/50	4.6 (50)	100	50/50
13-7	4.7 (49)	50/50	4.7 (50)	100	50/50	4.5 (50)	96	50/50	4.4 (49)	94	50/50
14-7	4.8 (50)	50/50	4.6 (50)	96	50/50	4.5 (50)	94	50/50	4.4 (49)	92	50/50
18-7	4.7 (50)	50/50	4.7 (50)	100	50/50	4.6 (50)	98	50/50	4.5 (49)	96	50/50
22-7	4.6 (50)	50/50	4.6 (50)	100	50/50	4.4 (49)	96	49/50	4.5 (50)	98	50/50
26-7	4.8 (50)	50/50	4.6 (50)	96	50/50	4.5 (49)	94	49/50	4.5 (50)	94	50/50
30-7	4.7 (50)	50/50	4.7 (50)	100	50/50	4.5 (49)	96	49/50	4.6 (49)	98	49/50
34-7	4.7 (50)	50/50	4.6 (50)	98	50/50	4.5 (49)	96	49/50	4.5 (49)	96	49/50
38-7	4.4 (50)	50/50	4.4 (50)	100	50/50	4.3 (49)	98	49/50	4.2 (49)	95	49/50
42-7	4.6 (50)	50/50	4.5 (50)	98	50/50	4.5 (49)	98	49/50	4.4 (48)	96	48/50
46-7	4.6 (50)	50/50	4.7 (50)	102	50/50	4.6 (49)	100	49/50	4.6 (48)	100	48/50
50-7	4.6 (50)	50/50	4.5 (49)	98	49/50	4.5 (49)	98	49/50	4.4 (48)	96	48/50
54-7	4.7 (50)	50/50	4.6 (48)	98	48/50	4.6 (49)	98	49/50	4.5 (48)	96	48/50
58-7	4.5 (50)	50/50	4.5 (48)	100	48/50	4.4 (49)	98	49/50	4.3 (47)	96	47/50
62-7	4.4 (50)	50/50	4.7 (48)	107	48/50	4.6 (49)	105	49/50	4.5 (47)	102	47/50
66-7	4.4 (48)	48/50	4.5 (47)	102	47/50	4.5 (47)	102	47/50	4.4 (45)	100	45/50
70-7	4.4 (45)	45/50	4.5 (45)	102	45/50	4.6 (45)	105	45/50	4.6 (43)	105	43/50
74-7	4.5 (45)	45/50	4.6 (43)	102	43/50	4.6 (45)	102	45/50	4.3 (40)	96	40/50
78-7	4.7 (43)	43/50	4.8 (41)	102	41/50	4.7 (44)	100	44/50	4.4 (38)	94	38/50
82-7	4.6 (39)	39/50	4.6 (39)	100	39/50	4.5 (44)	98	44/50	4.7 (37)	102	37/50
86-7	4.4 (37)	37/50	4.6 (31)	105	31/50	4.8 (37)	109	37/50	4.5 (32)	102	32/50
90-7	4.7 (36)	36/50	4.9 (27)	104	27/50	4.8 (33)	102	33/50	4.5 (26)	96	26/50
94-7	4.8 (31)	31/50	5.0 (23)	104	23/50	4.9 (30)	102	30/50	5.1 (20)	106	20/50
98-7	4.8 (29)	29/50	5.1 (20)	106	20/50	5.1 (27)	106	27/50	4.9 (14)	102	14/50
102-7	4.6 (27)	27/50	5.2 (15)	113	15/50	4.9 (24)	107	24/50	4.7 (12)	102	12/50
104-7	4.9 (27)	27/50	6.0 (15)	122	15/50	5.4 (19)	110	19/50	5.5 (9)	112	9/50

< >:No.of effective animals, ( ):No.of measured animals Av.FC.: g

TABLE E3

FOOD CONSUMPTION CHANGES : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	4.3± 0.3	4.2± 0.3	4.3± 0.3	4.3± 0.3	4.4± 0.3	4.4± 0.3	4.4± 0.3
0.6ppm	4.2± 0.2*	4.1± 0.3	4.3± 0.3	4.3± 0.3	4.3± 0.3	4.4± 0.3	4.3± 0.3
2.5ppm	4.2± 0.3	4.3± 0.3	4.4± 0.4	4.5± 0.4	4.6± 0.5	4.5± 0.4	4.5± 0.4
10ppm	4.1± 0.2**	4.1± 0.2	4.2± 0.3	4.2± 0.3	4.2± 0.3**	4.3± 0.3*	4.3± 0.3

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	4.5± 0.3	4.5± 0.3	4.6± 0.2	4.5± 0.3	4.6± 0.3	4.7± 0.3	4.6± 0.3
0.6ppm	4.4± 0.3	4.4± 0.3	4.5± 0.3	4.4± 0.3	4.5± 0.3	4.6± 0.3	4.6± 0.3
2.5ppm	4.6± 0.4	4.6± 0.4	4.7± 0.3	4.7± 0.3	4.7± 0.4	4.7± 0.3	4.7± 0.4
10ppm	4.4± 0.3	4.4± 0.4	4.4± 0.3	4.4± 0.3	4.5± 0.3	4.5± 0.3*	4.5± 0.3

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 18-7(7)	22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)
Control	4.8± 0.3	4.7± 0.3	4.9± 0.3	4.8± 0.3	4.8± 0.3	4.6± 0.3	4.6± 0.4
0.6ppm	4.7± 0.3	4.6± 0.3	4.8± 0.3	4.7± 0.3	4.7± 0.4	4.6± 0.4	4.7± 0.3
2.5ppm	4.8± 0.3	4.7± 0.4	4.8± 0.3	4.6± 0.4	4.7± 0.4	4.7± 0.3	4.7± 0.4
10ppm	4.6± 0.3**	4.5± 0.3	4.7± 0.3**	4.6± 0.3	4.5± 0.3**	4.5± 0.3	4.5± 0.3

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 46-7(7)	50-7(7)	54-7(7)	58-7(7)	62-7(7)	66-7(7)	70-7(7)
Control	4.9± 0.3	4.8± 0.4	4.9± 0.4	4.9± 0.5	4.8± 0.6	4.8± 0.5	4.7± 0.5
0.6ppm	4.8± 0.4	4.8± 0.6	4.9± 0.3	4.9± 0.4	4.8± 0.5	4.8± 0.5	4.7± 0.6
2.5ppm	5.0± 0.3	4.9± 0.5	5.0± 0.5	4.9± 0.5	4.8± 0.5	4.8± 0.6	4.9± 0.6
10ppm	4.8± 0.3	4.6± 0.3**	4.7± 0.5	4.6± 0.6**	4.6± 0.4	4.5± 0.4**	4.6± 0.5

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 74-7(7)	78-7(7)	82-7(7)	86-7(7)	90-7(7)	94-7(7)	98-7(7)
Control	4.7± 0.5	5.0± 0.7	4.8± 0.6	4.7± 0.5	4.8± 0.4	5.0± 0.6	5.1± 0.5
0.6ppm	4.7± 0.6	4.8± 0.6	4.7± 0.4	4.7± 0.6	4.9± 0.5	4.8± 0.6	5.0± 0.6
2.5ppm	4.6± 0.7	4.9± 0.6	4.8± 0.5	4.7± 0.5	4.9± 0.8	5.0± 0.6	5.0± 0.8
10ppm	4.3± 0.6**	4.5± 0.6**	4.5± 0.8*	4.5± 0.8	4.6± 0.7	4.5± 0.6*	4.4± 0.5**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 102-7(7)	104-7(7)
Control	5.0± 0.7	5.3± 1.0
0.6ppm	4.8± 0.6	5.1± 0.9
2.5ppm	4.8± 0.5	5.1± 0.9
10ppm	4.4± 0.5**	4.6± 0.3**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE E4

FOOD CONSUMPTION CHANGES : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	3.6± 0.3	3.7± 0.3	4.1± 0.4	4.3± 0.8	4.4± 0.7	4.7± 1.0	4.6± 0.4
0.6ppm	3.5± 0.3	3.6± 0.2	3.9± 0.2**	4.0± 0.3**	4.2± 0.3**	4.4± 0.5**	4.4± 0.6*
2.5ppm	3.5± 0.3	3.5± 0.2**	3.9± 0.3**	4.1± 0.3**	4.2± 0.3	4.3± 0.3**	4.4± 0.3
10ppm	3.5± 0.2	3.5± 0.3**	3.8± 0.3**	4.0± 0.3**	4.1± 0.5**	4.1± 0.4**	4.3± 0.4**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	4.7± 0.6	4.7± 0.9	4.7± 0.4	4.6± 0.4	4.6± 0.3	4.7± 0.6	4.8± 0.7
0.6ppm	4.6± 1.1*	4.6± 1.0	4.6± 0.9*	4.5± 0.3	4.5± 0.3	4.7± 1.1	4.6± 0.3
2.5ppm	4.6± 0.6	4.5± 0.3	4.5± 0.3	4.5± 0.3	4.5± 0.3	4.5± 0.5**	4.5± 0.4*
10ppm	4.4± 0.3**	4.4± 0.3	4.5± 0.5*	4.6± 0.6	4.6± 0.6	4.4± 0.4**	4.4± 0.3**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 18-7(7)	22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)
Control	4.7± 0.4	4.6± 0.5	4.8± 0.4	4.7± 0.4	4.7± 0.4	4.4± 0.4	4.6± 0.4
0.6ppm	4.7± 0.6	4.6± 0.4	4.6± 0.5*	4.7± 0.4	4.6± 0.4	4.4± 0.3	4.5± 0.4
2.5ppm	4.6± 0.4	4.4± 0.4*	4.5± 0.3**	4.5± 0.4*	4.5± 0.4*	4.3± 0.3	4.5± 0.4
10ppm	4.5± 0.3**	4.5± 0.4	4.5± 0.3**	4.6± 0.4	4.5± 0.3*	4.2± 0.4**	4.4± 0.3

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 46-7(7)	50-7(7)	54-7(7)	58-7(7)	62-7(7)	66-7(7)	70-7(7)
Control	4.6± 0.4	4.6± 0.4	4.7± 0.4	4.5± 0.4	4.4± 0.4	4.4± 0.5	4.4± 0.4
0.6ppm	4.7± 0.6	4.5± 0.4	4.6± 0.5	4.5± 0.6	4.7± 0.6*	4.5± 0.6	4.5± 0.6
2.5ppm	4.6± 0.4	4.5± 0.4	4.6± 0.4	4.4± 0.4	4.6± 0.5	4.5± 0.4	4.6± 0.5
10ppm	4.6± 0.3	4.4± 0.4	4.5± 0.5	4.3± 0.4	4.5± 0.4	4.4± 0.4	4.6± 0.6

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 74-7(7)	78-7(7)	82-7(7)	86-7(7)	90-7(7)	94-7(7)	98-7(7)
Control	4.5± 0.4	4.7± 0.8	4.6± 0.5	4.4± 0.4	4.7± 0.7	4.8± 1.0	4.8± 0.7
0.6ppm	4.6± 0.5	4.8± 1.1	4.6± 0.6	4.6± 0.7	4.9± 0.8	5.0± 0.7	5.1± 1.0
2.5ppm	4.6± 0.5	4.7± 0.7	4.5± 0.9	4.8± 1.0	4.8± 0.9	4.9± 0.9	5.1± 0.8
10ppm	4.3± 0.4	4.4± 0.5	4.7± 0.6	4.5± 0.4	4.5± 0.4	5.1± 1.1	4.9± 0.7

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration 102-7(7)	week-day(effective) 104-7(7)
Control	4.6± 0.7	4.9± 0.8
0.6ppm	5.2± 0.8	6.0± 1.1**
2.5ppm	4.9± 0.7	5.4± 1.0
10ppm	4.7± 0.5	5.5± 1.1

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE F1

HEMATOLOGY : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RED BLOOD CELL $10^6/\mu\ell$	HEMOGLOBIN g/dℓ	HEMATOCRIT %	MCV fℓ	MCH pg	MCHC g/dℓ	PLATELET $10^3/\mu\ell$
Control	26	9.17± 1.25	12.8± 1.9	40.2± 5.9	43.8± 3.0	13.9± 0.9	31.8± 0.8	2157± 528
0.6ppm	24	8.28± 2.02	11.8± 2.8	37.6± 8.0	46.0± 3.3	14.4± 0.7	31.3± 1.3	2054± 447
2.5ppm	14	8.54± 1.75	12.4± 2.6	39.6± 7.8	46.9± 4.9	14.6± 1.0	31.2± 1.5	1869± 671
10ppm	13	9.09± 0.54	13.0± 0.8	40.3± 2.3	44.3± 1.7	14.3± 0.5	32.3± 0.5	1903± 242*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RETICULOCYTE %
Control	26	3.2± 1.6
0.6ppm	24	4.6± 3.8
2.5ppm	14	4.2± 4.9
10ppm	13	2.9± 0.6

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	WBC $10^3/\mu\ell$		Differential WBC (%) NEUTRO		LYMPHO		MONO		EOSINO		BASO		OTHER	
Control	26	4.55±	2.05	49±	14	45±	14	4±	7	2±	1	0±	0	0±	0
0.6ppm	24	3.19±	1.59	53±	10	41±	10	3±	2	2±	1	0±	0	0±	1
2.5ppm	14	3.83±	1.91	55±	16	38±	15	5±	5	2±	1	0±	0	0±	0
10ppm	13	3.49±	1.10	54±	14	39±	14	5±	5	2±	1	0±	0	0±	0

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE F2

HEMATOLOGY : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RED BLOOD CELL $10^6/\mu\ell$	HEMOGLOBIN g/dℓ	HEMATOCRIT %	MCV fℓ	MCH pg	MCHC g/dℓ	PLATELET $10^3/\mu\ell$
Control	25	8.74± 1.59	12.6± 2.2	40.0± 6.0	46.4± 3.9	14.4± 0.8	31.2± 1.7	1252± 391
0.6ppm	14	8.28± 1.73	12.3± 2.2	39.5± 5.5	48.8± 6.1	15.1± 1.3	31.1± 1.7	1039± 366
2.5ppm	19	8.08± 1.13	11.9± 1.6	38.7± 4.5	48.3± 4.4	14.8± 1.0	30.7± 1.3	1289± 512
10ppm	9	8.22± 1.12	12.2± 1.7	39.4± 5.1	48.1± 3.5	14.8± 1.0	30.8± 0.9	1233± 355

Significant difference ; * : $P \leqq 0.05$ ** : $P \leqq 0.01$ Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RETICULOCYTE %
Control	25	5.0± 6.9
0.6ppm	14	6.7± 6.8
2.5ppm	19	6.7± 5.2
10ppm	9	4.9± 2.0

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	WBC $10^3/\mu\ell$		Differential WBC (%) NEUTRO		LYMPHO		MONO		EOSINO		BASO		OTHER	
Control	25	5.98±	10.60	38±	15	57±	16	3±	3	2±	1	0±	1	1±	1
0.6ppm	14	4.51±	2.69	46±	13	49±	13	2±	1	2±	1	0±	0	1±	1
2.5ppm	19	3.29±	1.72	45±	18	50±	18	2±	2	2±	1	0±	0	1±	1
10ppm	9	4.88±	5.04	37±	18	59±	19	2±	1	2±	1	0±	0	1±	1

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE G1

BIOCHEMISTRY : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	TOTAL PROTEIN g／dℓ	ALBUMIN g／dℓ	A/G RATIO	T-BILIRUBIN mg／dℓ	GLUCOSE mg／dℓ	T-CHOLESTEROL mg／dℓ	TRIGLYCERIDE mg／dℓ
Control	26	5.2± 0.8	2.3± 0.4	0.8± 0.2	0.06± 0.06	177± 47	128± 36	43± 25
0.6ppm	25	4.9± 0.9	2.3± 0.5	0.9± 0.2	0.04± 0.02	175± 67	138± 68	45± 27
2.5ppm	14	4.8± 0.9	2.3± 0.3	1.0± 0.3	0.06± 0.05	171± 67	119± 30	39± 21
10ppm	13	5.0± 0.4	2.3± 0.3	0.9± 0.2	0.05± 0.01	191± 38	108± 12	34± 10

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dℓ	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Control	26	216± 59	147± 217	68± 81	393± 541	264± 207	0.5± 0.5	599± 2453
0.6ppm	25	221± 83	306± 748	322± 960	1653± 4552	215± 94	0.4± 0.3	158± 206
2.5ppm	14	211± 56	187± 347	69± 139	388± 464	207± 101	1.1± 2.7	275± 651
10ppm	13	188± 31	103± 109	30± 26	242± 101	166± 44	0.4± 0.3	106± 112

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	UREA NITROGEN mg／dℓ	SODIUM mEq／ℓ	POTASSIUM mEq／ℓ	CHLORIDE mEq／ℓ	CALCIUM mg／dℓ	INORGANIC PHOSPHORUS mg／dℓ
Control	26	32.8± 15.7	156± 2	4.2± 0.4	123± 3	9.3± 0.7	5.6± 1.0
0.6ppm	25	45.7± 44.2	157± 4	4.2± 0.4	124± 6	9.1± 0.7	6.9± 4.1
2.5ppm	14	46.6± 43.8	159± 8	4.3± 0.7	125± 3	9.2± 0.6	7.0± 4.5
10ppm	13	25.8± 5.9	155± 2	4.1± 0.2	121± 5	8.9± 0.4	5.1± 0.8

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE G2

BIOCHEMISTRY : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	TOTAL PROTEIN g／dℓ	ALBUMIN g／dℓ	A/G RATIO	T-BILIRUBIN mg／dℓ	GLUCOSE mg／dℓ	T-CHOLESTEROL mg／dℓ	TRIGLYCERIDE mg／dℓ
Control	25	4.7± 0.7	2.4± 0.3	1.0± 0.2	0.04± 0.03	142± 42	98± 44	44± 29
0.6ppm	14	4.9± 0.6	2.5± 0.3	1.0± 0.2	0.06± 0.04	123± 49	100± 33	69± 69
2.5ppm	19	5.1± 0.6	2.5± 0.3	1.0± 0.2	0.08± 0.10	139± 47	106± 36	39± 19
10ppm	9	5.0± 0.5	2.5± 0.1	1.0± 0.1	0.05± 0.03	130± 60	107± 22	44± 45

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dℓ	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Control	25	175± 57	235± 600	135± 496	1065± 3648	524± 369	0.4± 0.2	288± 438
0.6ppm	14	181± 62	187± 188	68± 85	1509± 2628	367± 203	0.4± 0.3	216± 209
2.5ppm	19	185± 46	190± 312	71± 157	773± 1235	478± 320	0.5± 0.5	205± 236
10ppm	9	177± 48	140± 109	40± 26	846± 1730	655± 479	0.5± 0.4	259± 379

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	UREA NITROGEN mg／dℓ		SODIUM mEq／ℓ		POTASSIUM mEq／ℓ		CHLORIDE mEq／ℓ		CALCIUM mg／dℓ		INORGANIC PHOSPHORUS mg／dℓ	
Control	25	32.0±	22.5	155±	3	4.0±	0.7	125±	4	9.4±	0.4	6.8±	2.2
0.6ppm	14	29.3±	24.3	155±	4	4.3±	0.9	125±	5	9.5±	0.7	7.2±	2.4
2.5ppm	19	35.0±	22.4	155±	3	4.2±	1.1	124±	4	9.8±	0.5	6.9±	2.1
10ppm	9	47.2±	35.4	155±	1	4.5±	1.7	126±	5	9.5±	0.4	7.5±	2.2

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE H1

URINALYSIS : MALE

STUDY NO. : 0795 URINALYSIS
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

Group Name	NO. of Animals	pH 5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHI	Protein −	±	+	2+	3+	4+	CHI	Glucose −	±	+	2+	3+	4+	CHI	Ketone body −	±	+	2+	3+	4+	CHI	Occult blood −	±	+	2+	3+	CHI
Control	26	0	9	9	5	3	0	0		0	17	8	1	0	0		26	0	0	0	0	0		5	18	3	0	0	0		26	0	0	0	0	
0.6ppm	26	0	6	12	5	3	0	0		0	19	5	1	1	0		26	0	0	0	0	0		9	14	3	0	0	0		23	1	1	0	1	
2.5ppm	17	0	8	8	0	1	0	0		1	12	3	1	0	0		17	0	0	0	0	0		6	10	1	0	0	0		15	0	2	0	0	
10ppm	15	0	4	4	1	3	3	0		0	12	3	0	0	0		15	0	0	0	0	0		2	12	1	0	0	0		12	0	2	0	1	

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

STUDY NO. : 0795 URINALYSIS
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

Group Name	NO. of Animals	Urobilinogen ±	+	2+	3+	4+	CHI
Control	26	26	0	0	0	0	
0.6ppm	26	26	0	0	0	0	
2.5ppm	17	17	0	0	0	0	
10ppm	15	15	0	0	0	0	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

TABLE H2

URINALYSIS : FEMALE

STUDY NO. : 0795 URINALYSIS
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

Group Name	NO. of Animals	pH 5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHI	Protein −	±	+	2+	3+	4+	CHI	Glucose −	±	+	2+	3+	4+	CHI	Ketone body −	±	+	2+	3+	4+	CHI	Occult blood −	±	+	2+	3+	CHI
Control	27	0	9	12	4	1	1	0		10	12	3	0	2	0		27	0	0	0	0	0		19	7	1	0	0	0		26	0	0	0	1	
0.6ppm	15	0	2	10	1	0	2	0		7	6	1	0	1	0		15	0	0	0	0	0		10	3	2	0	0	0		14	0	0	0	1	
2.5ppm	22	0	9	10	2	1	0	0		15	5	1	1	0	0		22	0	0	0	0	0		17	4	1	0	0	0		22	0	0	0	0	
10ppm	9	0	3	6	0	0	0	0		4	5	0	0	0	0		9	0	0	0	0	0		8	1	0	0	0	0		9	0	0	0	0	

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

STUDY NO. : 0795 URINALYSIS
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

Group Name	NO. of Animals	Urobilinogen ±	+	2+	3+	4+	CHI
Control	27	27	0	0	0	0	
0.6ppm	15	15	0	0	0	0	
2.5ppm	22	22	0	0	0	0	
10ppm	9	9	0	0	0	0	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

TABLE I 1

GROSS FINDINGS : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	0.6ppm 50 (%)	2.5ppm 50 (%)	10ppm 50 (%)
skin/app	nodule		0 (0)	0 (0)	0 (0)	1 (2)
	ulcer		0 (0)	0 (0)	1 (2)	0 (0)
	erosion		2 (4)	3 (6)	3 (6)	1 (2)
subcutis	edema		1 (2)	1 (2)	2 (4)	3 (6)
	mass		4 (8)	4 (8)	9 (18)	4 (8)
nasal cavit	nodule		0 (0)	0 (0)	1 (2)	0 (0)
lung	white zone		0 (0)	0 (0)	3 (6)	1 (2)
	red zone		1 (2)	1 (2)	0 (0)	3 (6)
	nodule		4 (8)	3 (6)	5 (10)	7 (14)
lymph node	enlarged		5 (10)	6 (12)	5 (10)	4 (8)
spleen	enlarged		3 (6)	4 (8)	5 (10)	1 (2)
	black zone		0 (0)	0 (0)	0 (0)	1 (2)
	nodule		0 (0)	0 (0)	0 (0)	2 (4)
heart	white		0 (0)	1 (2)	0 (0)	0 (0)
	nodule		0 (0)	1 (2)	0 (0)	0 (0)
salivary gl	enlarged		0 (0)	1 (2)	0 (0)	0 (0)
	nodule		1 (2)	0 (0)	0 (0)	0 (0)
stomach	gas		0 (0)	0 (0)	1 (2)	1 (2)
	forestomach:erosion		1 (2)	0 (0)	0 (0)	0 (0)
	forestomach:nodule		0 (0)	1 (2)	0 (0)	3 (6)
	forestomach:thick		0 (0)	2 (4)	0 (0)	1 (2)
	glandular stomach:thick		2 (4)	6 (12)	2 (4)	2 (4)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	0.6ppm 50	(%)	2.5ppm 50	(%)	10ppm 50	(%)
small intes	nodule		0	(0)	2	(4)	1	(2)	0	(0)
	gas		0	(0)	0	(0)	0	(0)	1	(2)
large intes	gas		0	(0)	0	(0)	0	(0)	1	(2)
liver	enlarged		0	(0)	2	(4)	3	(6)	1	(2)
	white zone		2	(4)	7	(14)	4	(8)	0	(0)
	red zone		0	(0)	2	(4)	1	(2)	3	(6)
	nodule		12	(24)	19	(38)	7	(14)	12	(24)
	cyst		0	(0)	0	(0)	2	(4)	1	(2)
	deformed		1	(2)	0	(0)	0	(0)	0	(0)
	adhesion		0	(0)	0	(0)	1	(2)	0	(0)
pancreas	nodule		1	(2)	0	(0)	0	(0)	0	(0)
kidney	enlarged		0	(0)	0	(0)	3	(6)	1	(2)
	small		0	(0)	0	(0)	0	(0)	1	(2)
	pale		1	(2)	0	(0)	0	(0)	0	(0)
	white zone		2	(4)	2	(4)	3	(6)	3	(6)
	nodule		2	(4)	0	(0)	1	(2)	1	(2)
	cyst		2	(4)	3	(6)	1	(2)	1	(2)
	deformed		14	(28)	10	(20)	9	(18)	11	(22)
	hydronephrosis		3	(6)	8	(16)	8	(16)	3	(6)
urin bladd	nodule		0	(0)	0	(0)	0	(0)	1	(2)
	urine:marked retention		3	(6)	7	(14)	10	(20)	2	(4)
adrenal	enlarged		1	(2)	0	(0)	0	(0)	0	(0)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	0.6ppm 50	(%)	2.5ppm 50	(%)	10ppm 50	(%)
testis	white		0	(0)	0	(0)	0	(0)	1	(2)
	nodule		0	(0)	0	(0)	1	(2)	0	(0)
epididymis	nodule		1	(2)	0	(0)	1	(2)	1	(2)
semin ves	white zone		1	(2)	0	(0)	0	(0)	0	(0)
	black zone		0	(0)	0	(0)	0	(0)	1	(2)
	nodule		0	(0)	0	(0)	1	(2)	0	(0)
	adhesion		1	(2)	0	(0)	0	(0)	0	(0)
prep/cli gl	enlarged		1	(2)	0	(0)	0	(0)	0	(0)
	nodule		3	(6)	4	(8)	1	(2)	0	(0)
	cyst		0	(0)	1	(2)	0	(0)	0	(0)
brain	red zone		0	(0)	0	(0)	1	(2)	1	(2)
	black zone		1	(2)	0	(0)	0	(0)	0	(0)
periph nerv	nodule		0	(0)	0	(0)	0	(0)	1	(2)
eye	turbid		0	(0)	0	(0)	1	(2)	0	(0)
Harder gl	enlarged		0	(0)	0	(0)	2	(4)	0	(0)
	nodule		0	(0)	0	(0)	1	(2)	1	(2)
muscle	nodule		1	(2)	0	(0)	0	(0)	0	(0)
bone	nodule		0	(0)	0	(0)	0	(0)	2	(4)
pleura	nodule		0	(0)	0	(0)	1	(2)	1	(2)
mediastinum	mass		1	(2)	0	(0)	0	(0)	1	(2)
peritoneum	nodule		0	(0)	2	(4)	0	(0)	2	(4)
	mass		0	(0)	1	(2)	0	(0)	0	(0)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	0.6ppm 50 (%)	2.5ppm 50 (%)	10ppm 50 (%)
peritoneum	adhesion		1 (2)	0 (0)	0 (0)	0 (0)
retroperit	mass		0 (0)	1 (2)	0 (0)	0 (0)
abdominal c	hemorrhage		0 (0)	2 (4)	0 (0)	0 (0)
	ascites		3 (6)	3 (6)	7 (14)	3 (6)
thoracic ca	hemorrhage		0 (0)	0 (0)	0 (0)	1 (2)
	pleural fluid		5 (10)	7 (14)	6 (12)	6 (12)
other	red		0 (0)	1 (2)	0 (0)	0 (0)
	scab		0 (0)	1 (2)	0 (0)	0 (0)
	upper jaw:nodule		0 (0)	1 (2)	0 (0)	0 (0)
	nose:nodule		0 (0)	0 (0)	0 (0)	1 (2)
whole body	anemic		0 (0)	0 (0)	1 (2)	2 (4)

TABLE I 2

GROSS FINDINGS : FEMALE

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	0.6ppm 50 (%)	2.5ppm 50 (%)	10ppm 50 (%)
skin/app	nodule		0 (0)	0 (0)	0 (0)	1 (2)
	erosion		0 (0)	0 (0)	1 (2)	0 (0)
	scab		0 (0)	1 (2)	1 (2)	0 (0)
subcutis	edema		3 (6)	2 (4)	2 (4)	5 (10)
	dry		0 (0)	0 (0)	1 (2)	0 (0)
	mass		3 (6)	6 (12)	3 (6)	4 (8)
nasal cavit	nodule		0 (0)	0 (0)	0 (0)	1 (2)
lung	red		0 (0)	0 (0)	1 (2)	0 (0)
	white zone		0 (0)	0 (0)	0 (0)	1 (2)
	red zone		2 (4)	2 (4)	0 (0)	1 (2)
	nodule		3 (6)	5 (10)	5 (10)	6 (12)
lymph node	enlarged		12 (24)	14 (28)	14 (28)	13 (26)
spleen	enlarged		11 (22)	10 (20)	10 (20)	8 (16)
	white zone		0 (0)	1 (2)	1 (2)	0 (0)
	red zone		1 (2)	0 (0)	0 (0)	0 (0)
	black zone		1 (2)	0 (0)	0 (0)	0 (0)
	nodule		0 (0)	1 (2)	0 (0)	1 (2)
	deformed		0 (0)	1 (2)	0 (0)	0 (0)
	adhesion		0 (0)	0 (0)	0 (0)	1 (2)
heart	white zone		1 (2)	0 (0)	0 (0)	0 (0)
	nodule		1 (2)	0 (0)	0 (0)	0 (0)
salivary gl	nodule		0 (0)	0 (0)	0 (0)	1 (2)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	0.6ppm 50	(%)	2.5ppm 50	(%)	10ppm 50	(%)
stomach	glandular stomach:ulcer		0	(0)	1	(2)	0	(0)	0	(0)
	glandular stomach:erosion		0	(0)	1	(2)	0	(0)	0	(0)
	glandular stomach:nodule		1	(2)	0	(0)	0	(0)	0	(0)
	glandular stomach:thick		4	(8)	1	(2)	4	(8)	0	(0)
	glandular stomach:white zone		1	(2)	0	(0)	0	(0)	0	(0)
small intes	nodule		1	(2)	1	(2)	0	(0)	0	(0)
liver	enlarged		9	(18)	6	(12)	3	(6)	7	(14)
	white zone		9	(18)	8	(16)	8	(16)	9	(18)
	red zone		1	(2)	0	(0)	4	(8)	0	(0)
	nodule		2	(4)	7	(14)	6	(12)	7	(14)
	cyst		1	(2)	0	(0)	1	(2)	1	(2)
	rough		1	(2)	0	(0)	0	(0)	0	(0)
gall bladd	dilated		1	(2)	0	(0)	0	(0)	0	(0)
kidney	enlarged		1	(2)	2	(4)	1	(2)	2	(4)
	small		3	(6)	3	(6)	2	(4)	0	(0)
	white		0	(0)	0	(0)	1	(2)	0	(0)
	yellow		0	(0)	0	(0)	0	(0)	1	(2)
	white zone		2	(4)	2	(4)	2	(4)	0	(0)
	red zone		1	(2)	0	(0)	0	(0)	0	(0)
	brown zone		1	(2)	0	(0)	0	(0)	0	(0)
	nodule		1	(2)	1	(2)	0	(0)	0	(0)
	cyst		0	(0)	1	(2)	1	(2)	1	(2)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	0.6ppm 50	(%)	2.5ppm 50	(%)	10ppm 50	(%)
kidney	deformed		18	(36)	19	(38)	21	(42)	18	(36)
	hydronephrosis		3	(6)	3	(6)	4	(8)	3	(6)
ureter	dilated		1	(2)	0	(0)	0	(0)	0	(0)
urin bladd	urine:marked retention		0	(0)	0	(0)	0	(0)	1	(2)
pituitary	enlarged		0	(0)	7	(14)	3	(6)	3	(6)
	red zone		2	(4)	3	(6)	0	(0)	3	(6)
	nodule		1	(2)	1	(2)	4	(8)	0	(0)
ovary	enlarged		3	(6)	2	(4)	6	(12)	8	(16)
	cyst		10	(20)	6	(12)	8	(16)	7	(14)
uterus	nodule		11	(22)	10	(20)	11	(22)	16	(32)
	cyst		1	(2)	0	(0)	0	(0)	0	(0)
vagina	nodule		1	(2)	0	(0)	0	(0)	0	(0)
brain	red zone		0	(0)	1	(2)	0	(0)	0	(0)
	yellow zone		0	(0)	1	(2)	0	(0)	0	(0)
eye	turbid		0	(0)	0	(0)	0	(0)	1	(2)
	white		0	(0)	0	(0)	1	(2)	0	(0)
Harder gl	enlarged		0	(0)	0	(0)	1	(2)	2	(4)
	nodule		0	(0)	0	(0)	1	(2)	2	(4)
muscle	nodule		0	(0)	1	(2)	0	(0)	2	(4)
pleura	nodule		0	(0)	1	(2)	0	(0)	0	(0)
	thick		0	(0)	0	(0)	1	(2)	0	(0)
mediastinum	mass		2	(4)	2	(4)	1	(2)	0	(0)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	0.6ppm 50	(%)	2.5ppm 50	(%)	10ppm 50	(%)
peritoneum	nodule		0	(0)	3	(6)	1	(2)	1	(2)
	mass		0	(0)	0	(0)	0	(0)	1	(2)
	thick		0	(0)	1	(2)	1	(2)	0	(0)
retroperit	nodule		0	(0)	0	(0)	0	(0)	1	(2)
abdominal c	hemorrhage		1	(2)	1	(2)	2	(4)	2	(4)
	ascites		11	(22)	9	(18)	12	(24)	7	(14)
thoracic ca	pleural fluid		11	(22)	10	(20)	14	(28)	11	(22)
other	ear:nodule		0	(0)	0	(0)	1	(2)	0	(0)
	hindlimb:nodule		0	(0)	0	(0)	0	(0)	1	(2)
whole body	anemic		0	(0)	1	(2)	1	(2)	0	(0)

TABLE J1

ORGAN WEIGHT, ABSOLUTE : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	26	32.6± 4.7	0.021± 0.039	0.221± 0.034	0.195± 0.019	0.214± 0.051	0.606± 0.055
0.6ppm	25	32.7± 6.0	0.013± 0.002	0.240± 0.030	0.207± 0.029	0.204± 0.014	0.946± 1.540
2.5ppm	14	31.8± 4.0	0.014± 0.004	0.285± 0.152	0.189± 0.017	0.228± 0.048	0.598± 0.126
10ppm	13	33.1± 4.8	0.013± 0.002	0.226± 0.037	0.198± 0.021	0.199± 0.016	0.621± 0.063

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	26	0.111± 0.064	1.674± 0.560	0.476± 0.024
0.6ppm	25	0.112± 0.060	1.666± 0.619	0.474± 0.020
2.5ppm	14	0.136± 0.185	1.612± 0.734	0.481± 0.022
10ppm	13	0.111± 0.102	1.354± 0.179	0.468± 0.023

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE J2

ORGAN WEIGHT, ABSOLUTE : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	26	25.8± 2.4	0.016± 0.003	0.111± 0.134	0.174± 0.022	0.214± 0.060	0.454± 0.084
0.6ppm	14	28.7± 2.5**	0.016± 0.002	0.101± 0.096	0.189± 0.035	0.203± 0.023	0.510± 0.100
2.5ppm	19	27.2± 3.4	0.017± 0.005	0.123± 0.144	0.170± 0.023	0.193± 0.020	0.471± 0.101
10ppm	9	25.5± 2.6	0.015± 0.003	0.131± 0.255	0.167± 0.013	0.207± 0.049	0.570± 0.368

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	26	0.180± 0.173	1.494± 0.438	0.492± 0.026
0.6ppm	14	0.296± 0.333	1.790± 0.518	0.493± 0.020
2.5ppm	19	0.213± 0.184	1.750± 0.784	0.489± 0.016
10ppm	9	0.160± 0.097	1.390± 0.160	0.482± 0.024

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE K1

ORGAN WEIGHT, RELATIVE : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	26	32.6± 4.7	0.060± 0.089	0.690± 0.128	0.607± 0.088	0.666± 0.156	1.885± 0.237
0.6ppm	25	32.7± 6.0	0.041± 0.011	0.747± 0.114	0.645± 0.108	0.642± 0.123	2.913± 4.718
2.5ppm	14	31.8± 4.0	0.044± 0.013	0.898± 0.446	0.600± 0.076	0.726± 0.172	1.898± 0.450
10ppm	13	33.1± 4.8	0.040± 0.008	0.690± 0.110	0.607± 0.098	0.616± 0.123	1.899± 0.261

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	26	0.348± 0.205	5.239± 1.944	1.487± 0.208
0.6ppm	25	0.354± 0.222	5.191± 2.062	1.488± 0.240
2.5ppm	14	0.437± 0.615	5.109± 2.467	1.535± 0.204
10ppm	13	0.340± 0.293	4.107± 0.319	1.447± 0.263

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE K2

ORGAN WEIGHT, RELATIVE : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	26	25.8± 2.4	0.061± 0.013	0.426± 0.495	0.678± 0.078	0.830± 0.215	1.759± 0.247
0.6ppm	14	28.7± 2.5**	0.056± 0.008	0.364± 0.367	0.659± 0.120	0.709± 0.072**	1.767± 0.243
2.5ppm	19	27.2± 3.4	0.061± 0.014	0.441± 0.503	0.632± 0.102	0.717± 0.103**	1.739± 0.331
10ppm	9	25.5± 2.6	0.060± 0.008	0.482± 0.914	0.659± 0.068	0.826± 0.264	2.320± 1.792

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	26	0.701± 0.675	5.785± 1.608	1.924± 0.202
0.6ppm	14	0.992± 1.066	6.152± 1.272	1.727± 0.146**
2.5ppm	19	0.775± 0.664	6.353± 2.400	1.825± 0.201
10ppm	9	0.658± 0.482	5.472± 0.652	1.904± 0.185

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE L1

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : MALE

Organ	Findings	Group Name	Control				0.6ppm				2.5ppm				10ppm			
		No. of Animals on Study	50				50				50				50			
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Integumentary system/appandage}																		
skin/app			<50>				<50>				<50>				<50>			
	ulcer		0	2	0	0	1	0	0	0	1	1	0	0	0	0	0	0
			(0)	(4)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
	erosion		0	0	0	0	1	1	0	0	1	1	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(2)	(2)	(0)	(0)	(2)	(2)	(0)	(0)	(2)	(0)	(0)	(0)
subcutis			<50>				<50>				<50>				<50>			
	inflammation		0	2	0	0	0	0	0	0	0	5	0	0	0	2	0	0
			(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(4)	(0)	(0)
	xanthogranuloma		0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(2)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Respiratory system}																		
nasal cavit			<50>				<50>				<50>				<50>			
	angiectasis		0	0	0	0	0	0	0	0	1	0	0	0	2	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(2)	(0)	(0)
	thrombus		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Respiratory system}																		
nasal cavit		<50>					<50>				<50>				<50>			
	eosinophilic change:olfactory epithelium		3	0	0	0	7	1	0	0	7	0	0	0	15	0	0	0 **
			(6)	(0)	(0)	(0)	(14)	(2)	(0)	(0)	(14)	(0)	(0)	(0)	(30)	(0)	(0)	(0)
	eosinophilic change:respiratory epithelium		7	0	0	0	5	1	1	0	14	2	0	0	27	2	0	0 **
			(14)	(0)	(0)	(0)	(10)	(2)	(2)	(0)	(28)	(4)	(0)	(0)	(54)	(4)	(0)	(0)
	inflammation:respiratory epithelium		0	0	0	0	0	0	0	0	1	0	0	0	12	0	0	0 **
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(24)	(0)	(0)	(0)
	respiratory metaplasia:olfactory epithelium		4	0	0	0	15	1	0	0 *	22	10	0	0 **	0	46	0	0 **
			(8)	(0)	(0)	(0)	(30)	(2)	(0)	(0)	(44)	(20)	(0)	(0)	(0)	(92)	(0)	(0)
	respiratory metaplasia:gland		12	0	0	0	19	3	0	0 *	17	20	0	0 **	1	40	8	0 **
			(24)	(0)	(0)	(0)	(38)	(6)	(0)	(0)	(34)	(40)	(0)	(0)	(2)	(80)	(16)	(0)
	squamous cell metaplasia:respiratory epithelium		0	0	0	0	1	0	0	0	0	0	0	0	7	0	0	0 *
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(14)	(0)	(0)	(0)
	hyperplasia:transitional epithelium		0	0	0	0	0	0	0	0	2	0	0	0	15	5	0	0 **
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(30)	(10)	(0)	(0)
	regeneration:respiratory epithelium		0	0	0	0	0	0	0	0	5	0	0	0	14	0	0	0 **
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(28)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Respiratory system}																		
nasal cavit		<50>	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	regeneration:olfactory epithelium		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	atrophy:olfactory epithelium		0	0	0	0	2	0	0	0	2	0	0	0	3	0	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(6)	(0)	(0)	(0)
	necrosis:olfactory epithelium		1	0	0	0	0	0	0	0	1	0	0	0	3	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(6)	(0)	(0)	(0)
	necrosis:respiratory epithelium		0	0	0	0	0	0	0	0	2	0	0	0	3	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(6)	(0)	(0)	(0)
	hyperplasia:respiratory epithelium		0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
nasopharynx		<50>	2	0	0	0	3	3	0	0	3	0	0	0	14	1	0	0 **
	eosinophilic change		(4)	(0)	(0)	(0)	(6)	(6)	(0)	(0)	(6)	(0)	(0)	(0)	(28)	(2)	(0)	(0)
trachea		<50>	0	0	0	0	2	0	0	0	1	0	0	0	1	0	0	0
	eosinophilic change		(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Respiratory system}																		
lung		<50>	0	1	0	0	0	2	0	0	0	0	0	0	1	1	0	0
	congestion		(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(2)	(0)	(0)
	hemorrhage		1	0	0	0	2	0	0	0	1	0	0	0	1	0	0	0
			(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	edema		2	2	0	0	0	1	0	0	0	3	0	0	3	1	0	0
			(4)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(6)	(0)	(0)	(6)	(2)	(0)	(0)
	deposit of amyloid		19	3	0	0	15	2	0	0	13	1	0	0	9	0	0	0 *
			(38)	(6)	(0)	(0)	(30)	(4)	(0)	(0)	(26)	(2)	(0)	(0)	(18)	(0)	(0)	(0)
	inflammatory infiltration		3	0	0	0	3	0	0	0	2	0	0	0	0	0	0	0
			(6)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	bronchiolar-alveolar cell hyperplasia		0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
	eosinophilic change:bronchial epithelium		0	0	0	0	2	0	0	0	1	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	accumulation:macrophage		0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Hematopoietic system}																		
bone marrow		<50>																
	decreased hematopoiesis		7 (14)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	10 (20)	0 (0)	0 (0)	0 (0)
	myelofibrosis		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	erythropoiesis:increased		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	granulopoiesis:increased		2 (4)	7 (14)	1 (2)	0 (0)	5 (10)	2 (4)	1 (2)	0 (0)	13 (26)	2 (4)	1 (2)	0 * (0)	1 (2)	3 (6)	0 (0)	0 (0)
lymph node		<50>																
	lymphadenitis		3 (6)	1 (2)	0 (0)	0 (0)	1 (2)	3 (6)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
spleen		<50>																
	congestion		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of amyloid		2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Hematopoietic system}																		
spleen		<50>																
	deposit of melanin		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis		7 (14)	3 (6)	0 (0)	0 (0)	7 (14)	4 (8)	0 (0)	0 (0)	13 (26)	3 (6)	0 (0)	0 (0)	8 (16)	1 (2)	0 (0)	0 (0)
	follicular hyperplasia		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
{Circulatory system}																		
heart		<50>																
	thrombus		0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	necrosis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	necrosis:focal		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	deposit of amyloid		18 (36)	8 (16)	1 (2)	0 (0)	10 (20)	5 (10)	1 (2)	0 (0)	16 (32)	3 (6)	0 (0)	0 (0)	14 (28)	5 (10)	2 (4)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Circulatory system}																		
heart		<50>	0	0	0	0	1	0	0	0	1	0	0	0	2	0	0	0
	mineralization		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	inflammation		2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	myocardial fibrosis		0	0	0	0	1	0	1	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(2)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	arteritis		0	1	0	0	2	0	0	0	2	0	0	0	1	0	0	0
			(0)	(2)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
{Digestive system}																		
tooth		<50>	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
	dysplasia		(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
tongue		<50>	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	erosion		(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.6ppm 1+ (%)	0.6ppm 2+ (%)	0.6ppm 3+ (%)	0.6ppm 4+ (%)	2.5ppm 1+ (%)	2.5ppm 2+ (%)	2.5ppm 3+ (%)	2.5ppm 4+ (%)	10ppm 1+ (%)	10ppm 2+ (%)	10ppm 3+ (%)	10ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Digestive system}																		
tongue			<50>				<50>				<50>				<50>			
	deposit of amyloid		17	30	0	0	19	30	0	0	19	29	0	0	18	30	0	0
			(34)	(60)	(0)	(0)	(38)	(60)	(0)	(0)	(38)	(58)	(0)	(0)	(36)	(60)	(0)	(0)
	inflammatory infiltration		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	arteritis		1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
salivary gl			<50>				<50>				<50>				<50>			
	xanthogranuloma		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
stomach			<50>				<50>				<50>				<50>			
	deposit of amyloid		26	20	0	0	29	14	0	0	30	15	0	0	25	18	0	0
			(52)	(40)	(0)	(0)	(58)	(28)	(0)	(0)	(60)	(30)	(0)	(0)	(50)	(36)	(0)	(0)
	ulcer:forestomach		0	1	0	0	0	0	0	0	1	0	0	0	1	0	0	0
			(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	hyperplasia:forestomach		2	0	0	0	2	0	0	0	2	0	0	0	3	0	0	0
			(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(6)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Digestive system}																		
stomach		<50>					<50>				<50>				<50>			
	hyperkeratosis:forestomach		32	10	0	0	35	5	0	0	26	15	0	0	25	17	0	0
			(64)	(20)	(0)	(0)	(70)	(10)	(0)	(0)	(52)	(30)	(0)	(0)	(50)	(34)	(0)	(0)
	erosion:glandular stomach		4	0	0	0	3	0	0	0	1	0	0	0	2	0	0	0
			(8)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	hyperplasia:glandular stomach		11	34	2	0	8	35	2	0	12	36	0	0	14	31	0	0
			(22)	(68)	(4)	(0)	(16)	(70)	(4)	(0)	(24)	(72)	(0)	(0)	(28)	(62)	(0)	(0)
	erosion:pylorus		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	accumulation:macrophage		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
small intes		<50>					<50>				<50>				<50>			
	hemorrhage		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	deposit of amyloid		3	36	6	0	3	38	5	0	3	40	3	0	2	43	2	0
			(6)	(72)	(12)	(0)	(6)	(76)	(10)	(0)	(6)	(80)	(6)	(0)	(4)	(86)	(4)	(0)
	inflammation		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.6ppm 1+ (%)	0.6ppm 2+ (%)	0.6ppm 3+ (%)	0.6ppm 4+ (%)	2.5ppm 1+ (%)	2.5ppm 2+ (%)	2.5ppm 3+ (%)	2.5ppm 4+ (%)	10ppm 1+ (%)	10ppm 2+ (%)	10ppm 3+ (%)	10ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Digestive system}																		
small intes		<50>					<50>				<50>				<50>			
	lymphocytic infiltration		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphadenitis		11 (22)	3 (6)	0 (0)	0 (0)	11 (22)	10 (20)	1 (2)	0 (0)	9 (18)	6 (12)	1 (2)	0 (0)	8 (16)	7 (14)	1 (2)	0 (0)
	dilatation:tubular lumen		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
large intes		<50>					<50>				<50>				<50>			
	dilatation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
	deposit of amyloid		19 (38)	4 (8)	0 (0)	0 (0)	22 (44)	3 (6)	0 (0)	0 (0)	13 (26)	3 (6)	0 (0)	0 (0)	14 (28)	0 (0)	0 (0)	0 * (0)
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
liver		<50>					<50>				<50>				<50>			
	angiectasis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.6ppm 1+ (%)	0.6ppm 2+ (%)	0.6ppm 3+ (%)	0.6ppm 4+ (%)	2.5ppm 1+ (%)	2.5ppm 2+ (%)	2.5ppm 3+ (%)	2.5ppm 4+ (%)	10ppm 1+ (%)	10ppm 2+ (%)	10ppm 3+ (%)	10ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Digestive system}																		
liver		<50>					<50>				<50>				<50>			
	necrosis		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	necrosis:focal		1	3	0	0	0	2	0	0	2	0	0	0	0	0	0	0
			(2)	(6)	(0)	(0)	(0)	(4)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	deposit of amyloid		1	3	0	0	4	0	0	0	3	1	0	0	2	0	0	0
			(2)	(6)	(0)	(0)	(8)	(0)	(0)	(0)	(6)	(2)	(0)	(0)	(4)	(0)	(0)	(0)
	granulation		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory cell nest		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	extramedullary hematopoiesis		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	acidophilic cell focus		2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	basophilic cell focus		2	1	0	0	2	0	0	0	2	0	0	0	1	0	0	0
			(4)	(2)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control	0.6ppm	2.5ppm	10ppm
		No. of Animals on Study	50	50	50	50
		1+ (%)				
		2+ (%)				
		3+ (%)				
		4+ (%)				
{Digestive system}						
liver			<50>	<50>	<50>	<50>
	bile duct hyperplasia	1+	0 (0)	0 (0)	0 (0)	0 (0)
		2+	0 (0)	1 (2)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	biliary cyst	1+	0 (0)	0 (0)	0 (0)	0 (0)
		2+	0 (0)	0 (0)	1 (2)	1 (2)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	cyst	1+	0 (0)	0 (0)	2 (4)	0 (0)
		2+	4 (8)	2 (4)	0 (0)	2 (4)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 * (0)	0 (0)
	hyaline droplet	1+	1 (2)	1 (2)	4 (8)	1 (2)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of amyloid	1+	1 (2)	1 (2)	2 (4)	0 (0)
		2+	4 (8)	4 (8)	2 (4)	4 (8)
		3+	11 (22)	7 (14)	7 (14)	10 (20)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	inflammation	1+	0 (0)	1 (2)	0 (0)	1 (2)
		2+	1 (2)	0 (0)	3 (6)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	osseous metaplasia	1+	0 (0)	0 (0)	2 (4)	0 (0)
		2+	0 (0)	0 (0)	1 (2)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Urinary system}																		
kidney		<50>																
	papillomatous polyp		0 (0)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hydronephrosis		1 (2)	1 (2)	1 (2)	0 (0)	1 (2)	5 (10)	1 (2)	0 (0)	0 (0)	7 (14)	1 (2)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)
	papillary necrosis		2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)
	regeneration:proximal tubule		1 (2)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	urothelial hyperplasia:pelvis		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	nephrosclerosis		6 (12)	7 (14)	2 (4)	0 (0)	8 (16)	9 (18)	0 (0)	0 (0)	4 (8)	7 (14)	1 (2)	0 (0)	7 (14)	4 (8)	0 (0)	0 (0)
urin bladd		<50>																
	dilatation		0 (0)	3 (6)	0 (0)	0 (0)	1 (2)	6 (12)	0 (0)	0 (0)	0 (0)	10 (20)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	simple hyperplasia:transitional epithelium		2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.6ppm 1+ (%)	0.6ppm 2+ (%)	0.6ppm 3+ (%)	0.6ppm 4+ (%)	2.5ppm 1+ (%)	2.5ppm 2+ (%)	2.5ppm 3+ (%)	2.5ppm 4+ (%)	10ppm 1+ (%)	10ppm 2+ (%)	10ppm 3+ (%)	10ppm 4+ (%)
{Urinary system}																		
urin bladd			<50>				<50>				<50>				<50>			
	xanthogranuloma		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
urethra			<50>				<50>				<50>				<50>			
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Endocrine system}																		
pituitary			<49>				<50>				<50>				<50>			
	cyst		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	hyperplasia		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Rathke pouch		4 (8)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
thyroid			<50>				<50>				<50>				<50>			
	cyst		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				0.6ppm				2.5ppm				10ppm			
		No. of Animals on Study	50				50				50				50			
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Endocrine system}																		
adrenal			<50>				<50>				<50>				<50>			
	congestion		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	deposit of amyloid		18	13	0	0	21	10	0	0	19	9	0	0	18	15	0	0
			(36)	(26)	(0)	(0)	(42)	(20)	(0)	(0)	(38)	(18)	(0)	(0)	(36)	(30)	(0)	(0)
	spindle-cell hyperplasia		24	6	0	0	22	11	0	0	18	10	0	0	15	3	0	0
			(48)	(12)	(0)	(0)	(44)	(22)	(0)	(0)	(36)	(20)	(0)	(0)	(30)	(6)	(0)	(0)
	focal hypertrophy:cortex		1	1	0	0	2	0	0	0	1	0	0	0	1	0	0	0
			(2)	(2)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
{Reproductive system}																		
testis			<50>				<50>				<50>				<50>			
	deposit of amyloid		3	0	0	0	4	0	0	0	1	0	0	0	3	0	0	0
			(6)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(6)	(0)	(0)	(0)
	mineralization		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	xanthogranuloma		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Reproductive system}																		
epididymis		<50>																
	spermatogenic granuloma		1	2	0	0	0	0	0	0	2	1	0	0	0	0	1	0
			(2)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(2)	(0)	(0)	(0)	(0)	(2)	(0)
semin ves		<50>																
	adhesion		2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammation		0	0	0	0	0	0	0	0	0	2	0	0	1	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(2)	(2)	(0)	(0)
prostate		<50>																
	inflammation		2	0	0	0	2	0	0	0	0	1	0	0	1	0	0	0
			(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(2)	(0)	(0)	(0)
prep/cli gl		<50>																
	duct ectasia		0	3	0	0	0	5	0	0	1	1	0	0	0	1	0	0
			(0)	(6)	(0)	(0)	(0)	(10)	(0)	(0)	(2)	(2)	(0)	(0)	(0)	(2)	(0)	(0)
	inflammation		0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Nervous system}																		
brain		<50>																
	hemorrhage		0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.6ppm 1+ (%)	0.6ppm 2+ (%)	0.6ppm 3+ (%)	0.6ppm 4+ (%)	2.5ppm 1+ (%)	2.5ppm 2+ (%)	2.5ppm 3+ (%)	2.5ppm 4+ (%)	10ppm 1+ (%)	10ppm 2+ (%)	10ppm 3+ (%)	10ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Nervous system}																		
brain		<50>																
	mineralization		12 (24)	0 (0)	0 (0)	0 (0)	15 (30)	0 (0)	0 (0)	0 (0)	19 (38)	0 (0)	0 (0)	0 (0)	12 (24)	0 (0)	0 (0)	0 (0)
{Special sense organs/appendage}																		
eye		<50>																
	retinal atrophy		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	keratitis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	phthisis bulbi		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Harder gl		<50>																
	lymphocytic infiltration		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				0.6ppm				2.5ppm				10ppm			
		No. of Animals on Study	50				50				50				50			
		Grade	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Musculoskeletal system}																		
muscle			<50>				<50>				<50>				<50>			
	hematoma		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Body cavities}																		
peritoneum			<50>				<50>				<50>				<50>			
	inflammation		0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE L2

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : FEMALE

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Integumentary system/appandage}																		
skin/app		<50>																
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	papillomatosis		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
subcutis		<50>																
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Respiratory system}																		
nasal cavit		<50>																
	angiectasis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (8)	3 (6)	0 (0)	0 * (0)
	eosinophilic change:olfactory epithelium		9 (18)	2 (4)	0 (0)	0 (0)	12 (24)	2 (4)	0 (0)	0 (0)	8 (16)	1 (2)	0 (0)	0 (0)	37 (74)	0 (0)	0 (0)	0 ** (0)
	eosinophilic change:respiratory epithelium		23 (46)	12 (24)	0 (0)	0 (0)	34 (68)	12 (24)	1 (2)	0 * (0)	33 (66)	8 (16)	0 (0)	0 (0)	32 (64)	10 (20)	1 (2)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Respiratory system}																		
nasal cavit			<50>				<50>				<50>				<50>			
	inflammation:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)
	respiratory metaplasia:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	23 (46)	18 (36)	0 (0)	0 (0) **	19 (38)	30 (60)	0 (0)	0 (0) **	0 (0)	50 (100)	0 (0)	0 (0) **
	respiratory metaplasia:gland		16 (32)	0 (0)	0 (0)	0 (0)	20 (40)	23 (46)	4 (8)	0 (0) **	13 (26)	32 (64)	4 (8)	0 (0) **	0 (0)	45 (90)	5 (10)	0 (0) **
	squamous cell metaplasia:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	14 (28)	0 (0)	0 (0)	0 (0) **
	hyperplasia:transitional epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0) *
	regeneration:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0) *	29 (58)	1 (2)	0 (0)	0 (0) **
	regeneration:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	atrophy:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Respiratory system}																		
nasal cavit		<50>																
	necrosis:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 * (0)
	necrosis:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
nasopharynx		<50>																
	eosinophilic change		3 (6)	1 (2)	0 (0)	0 (0)	14 (28)	0 (0)	0 (0)	0 ** (0)	15 (30)	2 (4)	0 (0)	0 ** (0)	24 (48)	3 (6)	0 (0)	0 ** (0)
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
larynx		<50>																
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
trachea		<50>																
	eosinophilic change		2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
lung		<50>																
	edema		2 (4)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Respiratory system}																		
lung		<50>	10	0	0	0	6	0	0	0	8	0	0	0	4	0	0	0
	deposit of amyloid		(20)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(16)	(0)	(0)	(0)	(8)	(0)	(0)	(0)
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphocytic infiltration		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	granulomatous inflammation		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	bronchiolar-alveolar cell hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	eosinophilic change:bronchial epithelium		2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	accumulation:macrophage		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Hematopoietic system}																		
bone marrow		<50>	1	0	0	0	2	0	0	0	0	0	0	0	2	0	0	0
	decreased hematopoiesis		(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Hematopoietic system}																		
bone marrow		<50>																
	myelofibrosis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	erythropoiesis:increased		3 (6)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	granulopoiesis:increased		4 (8)	2 (4)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	1 (2)	3 (6)	3 (6)	0 (0)
lymph node		<50>																
	deposit of amyloid		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphadenitis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)
spleen		<50>																
	atrophy		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
	deposit of amyloid		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Hematopoietic system}																		
spleen		<50>																
	extramedullary hematopoiesis		18 (36)	2 (4)	0 (0)	0 (0)	17 (34)	3 (6)	0 (0)	0 (0)	19 (38)	1 (2)	0 (0)	0 (0)	23 (46)	2 (4)	0 (0)	0 (0)
	follicular hyperplasia		1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
{Circulatory system}																		
heart		<50>																
	thrombus		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	necrosis		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	deposit of amyloid		19 (38)	7 (14)	0 (0)	0 (0)	16 (32)	5 (10)	0 (0)	0 (0)	29 (58)	3 (6)	0 (0)	0 (0)	17 (34)	4 (8)	0 (0)	0 (0)
	mineralization		1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammation		0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Circulatory system}																		
heart		<50>																
	mastcell hyperplasia		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	myocardial fibrosis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	arteritis		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Digestive system}																		
tooth		<50>																
	dysplasia		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
tongue		<50>																
	deposit of amyloid		37 (74)	11 (22)	0 (0)	0 (0)	37 (74)	13 (26)	0 (0)	0 (0)	38 (76)	9 (18)	0 (0)	0 (0)	33 (66)	13 (26)	0 (0)	0 (0)
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
[Digestive system]																		
tongue		<50>																
	arteritis		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
stomach		<50>																
	deposit of amyloid		32 (64)	10 (20)	0 (0)	0 (0)	39 (78)	6 (12)	0 (0)	0 (0)	39 (78)	9 (18)	0 (0)	0 (0)	37 (74)	1 (2)	0 (0)	0 * (0)
	hyperplasia:forestomach		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	hyperkeratosis:forestomach		27 (54)	15 (30)	0 (0)	0 (0)	25 (50)	19 (38)	0 (0)	0 (0)	28 (56)	19 (38)	0 (0)	0 (0)	24 (48)	14 (28)	0 (0)	0 (0)
	erosion:glandular stomach		6 (12)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 * (0)	2 (4)	0 (0)	0 (0)	0 (0)
	hyperplasia:glandular stomach		10 (20)	36 (72)	2 (4)	0 (0)	12 (24)	34 (68)	0 (0)	0 (0)	8 (16)	39 (78)	0 (0)	0 (0)	21 (42)	23 (46)	0 (0)	0 * (0)
small intes		<50>																
	hemorrhage		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Digestive system}																		
small intes		<50>																
	deposit of amyloid		0	41	5	0	4	38	4	0	2	40	7	0	4	37	7	0
			(0)	(82)	(10)	(0)	(8)	(76)	(8)	(0)	(4)	(80)	(14)	(0)	(8)	(74)	(14)	(0)
	inflammation		0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	lymphadenitis		5	11	0	0	6	2	0	0 *	5	3	1	0	0	13	0	0
			(10)	(22)	(0)	(0)	(12)	(4)	(0)	(0)	(10)	(6)	(2)	(0)	(0)	(26)	(0)	(0)
large intes		<50>																
	deposit of amyloid		22	8	0	0	11	8	0	0 *	7	19	0	0 **	13	7	0	0
			(44)	(16)	(0)	(0)	(22)	(16)	(0)	(0)	(14)	(38)	(0)	(0)	(26)	(14)	(0)	(0)
liver		<50>																
	angiectasis		0	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)
	necrosis:focal		0	1	0	0	0	0	0	0	2	0	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	deposit of amyloid		0	0	0	0	3	0	0	0	2	1	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(4)	(2)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				0.6ppm				2.5ppm				10ppm			
		No. of Animals on Study	50				50				50				50			
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive system}																		
liver			<50>				<50>				<50>				<50>			
	granulation		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory cell nest		5	0	0	0	0	1	0	0 *	0	0	0	0	0	0	0	0
			(10)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	basophilic cell focus		0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
	biliary cyst		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
{Urinary system}																		
kidney			<50>				<50>				<50>				<50>			
	hyaline droplet		11	3	0	0	10	4	0	0	8	4	0	0	17	1	0	0
			(22)	(6)	(0)	(0)	(20)	(8)	(0)	(0)	(16)	(8)	(0)	(0)	(34)	(2)	(0)	(0)
	deposit of amyloid		0	0	1	0	0	1	5	0	2	2	2	0	2	1	0	0
			(0)	(0)	(2)	(0)	(0)	(2)	(10)	(0)	(4)	(4)	(4)	(0)	(4)	(2)	(0)	(0)
	lymphocytic infiltration		1	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(2)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Urinary system}																		
kidney		<50>					<50>				<50>				<50>			
	papillomatous polyp		4	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
			(8)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	hydronephrosis		1	5	1	0	0	2	0	0	0	3	1	0	0	2	2	0
			(2)	(10)	(2)	(0)	(0)	(4)	(0)	(0)	(0)	(6)	(2)	(0)	(0)	(4)	(4)	(0)
	papillary necrosis		11	2	0	0	6	1	0	0	11	3	0	0	4	1	0	0
			(22)	(4)	(0)	(0)	(12)	(2)	(0)	(0)	(22)	(6)	(0)	(0)	(8)	(2)	(0)	(0)
	mineralization:papilla		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
	mineralization:cortex		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	dilatation:tubular lumen		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	regeneration:proximal tubule		0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)
	nephrosclerosis		5	22	4	0	5	20	3	0	8	21	5	0	6	17	5	0
			(10)	(44)	(8)	(0)	(10)	(40)	(6)	(0)	(16)	(42)	(10)	(0)	(12)	(34)	(10)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.6ppm 1+ (%)	0.6ppm 2+ (%)	0.6ppm 3+ (%)	0.6ppm 4+ (%)	2.5ppm 1+ (%)	2.5ppm 2+ (%)	2.5ppm 3+ (%)	2.5ppm 4+ (%)	10ppm 1+ (%)	10ppm 2+ (%)	10ppm 3+ (%)	10ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Urinary system}																		
ureter		<50>					<50>				<50>				<50>			
	dilatation		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
urin bladd		<50>					<50>				<50>				<50>			
	dilatation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
{Endocrine system}																		
pituitary		<50>					<50>				<50>				<50>			
	cyst		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	hyperplasia		10 (20)	5 (10)	1 (2)	0 (0)	7 (14)	3 (6)	1 (2)	0 (0)	10 (20)	0 (0)	0 (0)	0 (0)	8 (16)	3 (6)	0 (0)	0 (0)
	Rathke pouch		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
adrenal		<50>					<50>				<50>				<50>			
	deposit of amyloid		25 (50)	23 (46)	0 (0)	0 (0)	28 (56)	21 (42)	0 (0)	0 (0)	29 (58)	21 (42)	0 (0)	0 (0)	31 (62)	16 (32)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.6ppm 50 1+ (%)	0.6ppm 50 2+ (%)	0.6ppm 50 3+ (%)	0.6ppm 50 4+ (%)	2.5ppm 50 1+ (%)	2.5ppm 50 2+ (%)	2.5ppm 50 3+ (%)	2.5ppm 50 4+ (%)	10ppm 50 1+ (%)	10ppm 50 2+ (%)	10ppm 50 3+ (%)	10ppm 50 4+ (%)
{Endocrine system}																		
adrenal		<a>	<50>				<50>				<50>				<50>			
	spindle-cell hyperplasia	a	0	50	0	0	1	47	1	0	2	46	2	0	6	43	0	0 *
		b	(0)	(100)	(0)	(0)	(2)	(94)	(2)	(0)	(4)	(92)	(4)	(0)	(12)	(86)	(0)	(0)
	focal hypertrophy:cortex	a	0	0	0	0	1	1	0	0	2	1	0	0	0	0	0	0
		b	(0)	(0)	(0)	(0)	(2)	(2)	(0)	(0)	(4)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
{Reproductive system}																		
ovary		<a>	<50>				<50>				<50>				<50>			
	hemorrhage	a	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		b	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
	thrombus	a	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
		b	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	cyst	a	4	13	12	0	8	3	12	0 *	13	7	13	0	7	10	8	0
		b	(8)	(26)	(24)	(0)	(16)	(6)	(24)	(0)	(26)	(14)	(26)	(0)	(14)	(20)	(16)	(0)
	deposit of amyloid	a	5	21	19	0	8	19	20	0	8	17	21	0	7	18	18	0
		b	(10)	(42)	(38)	(0)	(16)	(38)	(40)	(0)	(16)	(34)	(42)	(0)	(14)	(36)	(36)	(0)
uterus		<a>	<50>				<50>				<50>				<50>			
	angiectasis	a	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		b	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.6ppm 1+ (%)	0.6ppm 2+ (%)	0.6ppm 3+ (%)	0.6ppm 4+ (%)	2.5ppm 1+ (%)	2.5ppm 2+ (%)	2.5ppm 3+ (%)	2.5ppm 4+ (%)	10ppm 1+ (%)	10ppm 2+ (%)	10ppm 3+ (%)	10ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Reproductive system}																		
uterus			<50>				<50>				<50>				<50>			
	hyperplasia:gland		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	cystic endometrial hyperplasia		9	0	0	0	8	0	0	0	9	0	0	0	11	0	0	0
			(18)	(0)	(0)	(0)	(16)	(0)	(0)	(0)	(18)	(0)	(0)	(0)	(22)	(0)	(0)	(0)
mammary gl			<50>				<50>				<50>				<50>			
	hyperplasia		0	0	0	0	1	0	0	0	1	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
{Nervous system}																		
brain			<50>				<50>				<50>				<50>			
	mineralization		10	0	0	0	13	0	0	0	11	0	0	0	4	0	0	0
			(20)	(0)	(0)	(0)	(26)	(0)	(0)	(0)	(22)	(0)	(0)	(0)	(8)	(0)	(0)	(0)
{Special sense organs/appendage}																		
eye			<50>				<50>				<50>				<50>			
	regenaration:epithelium		0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.6ppm 1+ (%)	0.6ppm 2+ (%)	0.6ppm 3+ (%)	0.6ppm 4+ (%)	2.5ppm 1+ (%)	2.5ppm 2+ (%)	2.5ppm 3+ (%)	2.5ppm 4+ (%)	10ppm 1+ (%)	10ppm 2+ (%)	10ppm 3+ (%)	10ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Special sense organs/appendage}																		
eye		<a>	<50>				<50>				<50>				<50>			
	keratitis	b	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
		(c)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(2)	(0)	(0)	(0)
	phthisis bulbi	b	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
		(c)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Harder gl		<a>	<50>				<50>				<50>				<50>			
	hyperplasia	b	1	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
		(c)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
{Musculoskeletal system}																		
bone		<a>	<50>				<50>				<50>				<50>			
	ostitis fibrosa	b	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		(c)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Body cavities}																		
peritoneum		<a>	<50>				<50>				<50>				<50>			
	peritonitis	b	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0
		(c)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(2)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE M1

NUMBER OF ANIMALS WITH TUMORS

AND NUMBER OF TUMORS-TIME RELATED : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	0.6ppm	2.5ppm	10ppm
0 - 52	NO. OF EXAMINED ANIMALS		3	4	3	1
	NO. OF ANIMALS WITH TUMORS		0	1	0	0
	NO. OF ANIMALS WITH SINGLE TUMORS		0	1	0	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	0
	NO. OF MALIGNANT TUMORS		0	1	0	0
	NO. OF TOTAL TUMORS		0	1	0	0
53 - 78	NO. OF EXAMINED ANIMALS		4	4	7	8
	NO. OF ANIMALS WITH TUMORS		1	2	1	8
	NO. OF ANIMALS WITH SINGLE TUMORS		1	1	1	5
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	1	0	3
	NO. OF BENIGN TUMORS		0	1	0	2
	NO. OF MALIGNANT TUMORS		1	2	1	11
	NO. OF TOTAL TUMORS		1	3	1	13
79 - 104	NO. OF EXAMINED ANIMALS		17	16	24	27
	NO. OF ANIMALS WITH TUMORS		8	9	20	22
	NO. OF ANIMALS WITH SINGLE TUMORS		5	5	14	14
	NO. OF ANIMALS WITH MULTIPLE TUMORS		3	4	6	8
	NO. OF BENIGN TUMORS		7	7	8	13
	NO. OF MALIGNANT TUMORS		6	9	22	20
	NO. OF TOTAL TUMORS		13	16	30	33
105 - 105	NO. OF EXAMINED ANIMALS		26	26	16	14
	NO. OF ANIMALS WITH TUMORS		15	16	11	11
	NO. OF ANIMALS WITH SINGLE TUMORS		10	5	3	4
	NO. OF ANIMALS WITH MULTIPLE TUMORS		5	11	8	7
	NO. OF BENIGN TUMORS		9	12	8	15
	NO. OF MALIGNANT TUMORS		12	15	12	6
	NO. OF TOTAL TUMORS		21	27	20	21

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	0.6ppm	2.5ppm	10ppm
0 - 105	NO. OF EXAMINED ANIMALS		50	50	50	50
	NO. OF ANIMALS WITH TUMORS		24	28	32	41
	NO. OF ANIMALS WITH SINGLE TUMORS		16	12	18	23
	NO. OF ANIMALS WITH MULTIPLE TUMORS		8	16	14	18
	NO. OF BENIGN TUMORS		16	20	16	30
	NO. OF MALIGNANT TUMORS		19	27	35	37
	NO. OF TOTAL TUMORS		35	47	51	67

TABLE M2

NUMBER OF ANIMALS WITH TUMORS

AND NUMBER OF TUMORS-TIME RELATED : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	0.6ppm	2.5ppm	10ppm
0 - 52	NO. OF EXAMINED ANIMALS		0	1	1	2
	NO. OF ANIMALS WITH TUMORS		0	1	0	2
	NO. OF ANIMALS WITH SINGLE TUMORS		0	1	0	2
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	0
	NO. OF MALIGNANT TUMORS		0	1	0	2
	NO. OF TOTAL TUMORS		0	1	0	2
53 - 78	NO. OF EXAMINED ANIMALS		7	8	5	10
	NO. OF ANIMALS WITH TUMORS		5	6	5	9
	NO. OF ANIMALS WITH SINGLE TUMORS		5	5	3	6
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	1	2	3
	NO. OF BENIGN TUMORS		0	0	2	2
	NO. OF MALIGNANT TUMORS		5	7	5	10
	NO. OF TOTAL TUMORS		5	7	7	12
79 - 104	NO. OF EXAMINED ANIMALS		16	26	25	29
	NO. OF ANIMALS WITH TUMORS		16	22	24	28
	NO. OF ANIMALS WITH SINGLE TUMORS		9	14	20	16
	NO. OF ANIMALS WITH MULTIPLE TUMORS		7	8	4	12
	NO. OF BENIGN TUMORS		6	6	5	14
	NO. OF MALIGNANT TUMORS		19	25	24	32
	NO. OF TOTAL TUMORS		25	31	29	46
105 - 105	NO. OF EXAMINED ANIMALS		27	15	19	9
	NO. OF ANIMALS WITH TUMORS		19	14	17	8
	NO. OF ANIMALS WITH SINGLE TUMORS		12	4	9	2
	NO. OF ANIMALS WITH MULTIPLE TUMORS		7	10	8	6
	NO. OF BENIGN TUMORS		13	17	14	8
	NO. OF MALIGNANT TUMORS		13	11	13	12
	NO. OF TOTAL TUMORS		26	28	27	20

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	0.6ppm	2.5ppm	10ppm
0 - 105	NO. OF EXAMINED ANIMALS		50	50	50	50
	NO. OF ANIMALS WITH TUMORS		40	43	46	47
	NO. OF ANIMALS WITH SINGLE TUMORS		26	24	32	26
	NO. OF ANIMALS WITH MULTIPLE TUMORS		14	19	14	21
	NO. OF BENIGN TUMORS		19	23	21	24
	NO. OF MALIGNANT TUMORS		37	44	42	56
	NO. OF TOTAL TUMORS		56	67	63	80

TABLE N1

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name	Control	0.6ppm	2.5ppm	10ppm
		No. of animals on Study	50	50	50	50
{Integumentary system/appandage}						
skin/app			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	squamous cell carcinoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
subcutis			<50>	<50>	<50>	<50>
	hemangioma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	fibrosarcoma		1 (2%)	0 (0%)	1 (2%)	1 (2%)
	leiomyosarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	histiocytic sarcoma		0 (0%)	2 (4%)	1 (2%)	0 (0%)
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	0 (0%)	0 (0%)	3 (6%)
	hemangioma		0 (0%)	0 (0%)	3 (6%)	8 (16%)
	histiocytic sarcoma		0 (0%)	0 (0%)	2 (4%)	1 (2%)
	hemangiosarcoma		0 (0%)	0 (0%)	1 (2%)	10 (20%)
lung			<50>	<50>	<50>	<50>
	bronchiolar-alveolar adenoma		4 (8%)	2 (4%)	1 (2%)	6 (12%)
	hemangioma		0 (0%)	0 (0%)	1 (2%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Respiratory system}						
lung			<50>	<50>	<50>	<50>
	bronchiolar-alveolar carcinoma		1 (2%)	0 (0%)	6 (12%)	1 (2%)
{Hematopoietic system}						
bone marrow			<50>	<50>	<50>	<50>
	mastcytoma:malignant		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	hemangiosarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
lymph node			<50>	<50>	<50>	<50>
	malignant lymphoma		8 (16%)	7 (14%)	10 (20%)	3 (6%)
	mastcytoma:malignant		0 (0%)	1 (2%)	1 (2%)	0 (0%)
spleen			<50>	<50>	<50>	<50>
	mastcytoma:benign		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	hemangioma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	mastcytoma:malignant		0 (0%)	1 (2%)	1 (2%)	0 (0%)
	hemangiosarcoma		0 (0%)	1 (2%)	1 (2%)	2 (4%)
{Digestive system}						
oral cavity			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
salivary gl			<50>	<50>	<50>	<50>
	histiocytic sarcoma		1 (2%)	1 (2%)	0 (0%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Digestive system}						
stomach			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	1 (2%)	0 (0%)	3 (6%)
small intes			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	adenocarcinoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
liver			<50>	<50>	<50>	<50>
	hemangioma		2 (4%)	2 (4%)	1 (2%)	1 (2%)
	hepatocellular adenoma		6 (12%)	10 (20%)	4 (8%)	2 (4%)
	histiocytic sarcoma		0 (0%)	3 (6%)	4 (8%)	2 (4%)
	hemangiosarcoma		0 (0%)	2 (4%)	1 (2%)	3 (6%)
	hepatocellular carcinoma		5 (10%)	5 (10%)	2 (4%)	6 (12%)
pancreas			<50>	<50>	<50>	<50>
	islet cell adenoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	transitional cell carcinoma		0 (0%)	2 (4%)	1 (2%)	0 (0%)
urin bladd			<50>	<50>	<50>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	0 (0%)	2 (4%)
urethra			<50>	<50>	<50>	<50>
	hemangioma		0 (0%)	1 (2%)	0 (0%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Reproductive system}						
epididymis			<50>	<50>	<50>	<50>
	hemangioma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	histiocytic sarcoma		2 (4%)	0 (0%)	3 (6%)	1 (2%)
{Nervous system}						
periph nerv			<50>	<50>	<50>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
{Special sense organs/appendage}						
Harder gl			<50>	<50>	<50>	<50>
	adenoma		1 (2%)	1 (2%)	5 (10%)	5 (10%)
{Body cavities}						
mediastinum			<50>	<50>	<50>	<50>
	histiocytic sarcoma		1 (2%)	0 (0%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE N2

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : FEMALE

Organ	Findings	Group Name / No. of animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Integumentary system/appandage}						
skin/app			<50>	<50>	<50>	<50>
	fibrosarcoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
subcutis			<50>	<50>	<50>	<50>
	leiomyoma		2 (4%)	0 (0%)	1 (2%)	0 (0%)
	hemangioma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	fibrosarcoma		0 (0%)	2 (4%)	1 (2%)	1 (2%)
	leiomyosarcoma		1 (2%)	1 (2%)	1 (2%)	1 (2%)
	histiocytic sarcoma		0 (0%)	1 (2%)	0 (0%)	2 (4%)
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	hemangioma		0 (0%)	0 (0%)	3 (6%)	7 (14%)
	adenocarcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	hemangiosarcoma		0 (0%)	0 (0%)	1 (2%)	4 (8%)
lung			<50>	<50>	<50>	<50>
	bronchiolar-alveolar adenoma		2 (4%)	2 (4%)	2 (4%)	0 (0%)
	bronchiolar-alveolar carcinoma		0 (0%)	2 (4%)	0 (0%)	5 (10%)
{Hematopoietic system}						
lymph node			<50>	<50>	<50>	<50>
	histiocytic sarcoma		2 (4%)	0 (0%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Hematopoietic system}						
lymph node			<50>	<50>	<50>	<50>
	malignant lymphoma		18 (36%)	19 (38%)	19 (38%)	9 (18%)
	mastcytoma:malignant		0 (0%)	1 (2%)	0 (0%)	0 (0%)
spleen			<50>	<50>	<50>	<50>
	hemangioma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	malignant lymphoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	mastcytoma:malignant		0 (0%)	0 (0%)	0 (0%)	1 (2%)
{Digestive system}						
salivary gl			<50>	<50>	<50>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
stomach			<50>	<50>	<50>	<50>
	squamous cell papilloma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	squamous cell carcinoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
liver			<50>	<50>	<50>	<50>
	hemangioma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	hepatocellular adenoma		1 (2%)	1 (2%)	1 (2%)	0 (0%)
	histiocytic sarcoma		5 (10%)	5 (10%)	0 (0%)	5 (10%)
	hepatocellular carcinoma		0 (0%)	1 (2%)	3 (6%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Endocrine system}						
pituitary			<50>	<50>	<50>	<50>
	adenoma		4 (8%)	10 (20%)	9 (18%)	7 (14%)
thyroid			<50>	<50>	<50>	<50>
	follicular adenoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
{Reproductive system}						
ovary			<50>	<50>	<50>	<50>
	cystadenoma		4 (8%)	4 (8%)	0 (0%)	2 (4%)
	hemangioma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
uterus			<50>	<50>	<50>	<50>
	endometrial stromal polyp		3 (6%)	3 (6%)	2 (4%)	2 (4%)
	histiocytic sarcoma		11 (22%)	10 (20%)	12 (24%)	18 (36%)
mammary gl			<50>	<50>	<50>	<50>
	adenoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	adenocarcinoma		0 (0%)	1 (2%)	1 (2%)	1 (2%)
{Special sense organs/appendage}						
eye			<50>	<50>	<50>	<50>
	melanoma:malignant		0 (0%)	0 (0%)	1 (2%)	1 (2%)
Harder gl			<50>	<50>	<50>	<50>
	adenoma		1 (2%)	1 (2%)	2 (4%)	4 (8%)
{Musculoskeletal system}						
bone			<50>	<50>	<50>	<50>
	osteosarcoma		0 (0%)	1 (2%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name	Control	0.6ppm	2.5ppm	10ppm
		No. of animals on Study	50	50	50	50
{Body cavities}						
peritoneum			<50>	<50>	<50>	<50>
	leiomyosarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	histiocytic sarcoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
retroperit			<50>	<50>	<50>	<50>
	leiomyosarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE O1

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS : MALE

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : nasal cavity			
	TUMOR : adenoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	0/50(0.0)	3/50(6.0)
Adjusted rates(b)	0.0	0.0	0.0	14.29
Terminal rates(c)	0/26(0.0)	0/26(0.0)	0/15(0.0)	2/14(14.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -------			
Prevalence method(d)	P = 0.0009**?			
Combined analysis(d)	P = -------			
Cochran-Armitage test(e)	P = 0.0033**			
Fisher Exact test(e)		P = N.C.	P = N.C.	P = 0.1212
	SITE : nasal cavity			
	TUMOR : hemangioma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	3/50(6.0)	8/50(16.0)
Adjusted rates(b)	0.0	0.0	14.29	28.57
Terminal rates(c)	0/26(0.0)	0/26(0.0)	2/15(13.3)	4/14(28.6)
Statistical analysis				
Peto test				
Standard method(d)	P = -------			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P = -------			
Cochran-Armitage test(e)	P = 0.0001**			
Fisher Exact test(e)		P = N.C.	P = 0.1212	P = 0.0029**
	SITE : nasal cavity			
	TUMOR : hemangiosarcoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	1/50(2.0)	10/50(20.0)
Adjusted rates(b)	0.0	0.0	5.88	7.14
Terminal rates(c)	0/26(0.0)	0/26(0.0)	0/15(0.0)	1/14(7.1)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P = 0.0299*			
Combined analysis(d)	P < 0.0001**			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = 0.5000	P = 0.0006**

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : nasal cavity			
	TUMOR : hemangioma, hemangiosarcoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	4/50(8.0)	16/50(32.0)
Adjusted rates(b)	0.0	0.0	19.05	35.71
Terminal rates(c)	0/26(0.0)	0/26(0.0)	2/15(13.3)	5/14(35.7)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = 0.0587	P < 0.0001**
	SITE : nasal cavity			
	TUMOR : hemangioma, hemangiosarcoma, adenoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	4/50(8.0)	19/50(38.0)
Adjusted rates(b)	0.0	0.0	19.05	50.00
Terminal rates(c)	0/26(0.0)	0/26(0.0)	2/15(13.3)	7/14(50.0)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = 0.0587	P < 0.0001**
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma			
Tumor rate				
Overall rates(a)	4/50(8.0)	2/50(4.0)	1/50(2.0)	6/50(12.0)
Adjusted rates(b)	11.43	7.14	5.88	28.57
Terminal rates(c)	2/26(7.7)	1/26(3.8)	0/15(0.0)	4/14(28.6)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0407*			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.1289			
Fisher Exact test(e)		P = 0.3389	P = 0.1811	P = 0.3703

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : lung			
	TUMOR : bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	0/50(0.0)	6/50(12.0)	1/50(2.0)
Adjusted rates(b)	3.85	0.0	25.00	0.0
Terminal rates(c)	1/26(3.8)	0/26(0.0)	3/15(20.0)	0/14(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1443			
Prevalence method(d)	P = 0.6152			
Combined analysis(d)	P = 0.3589			
Cochran-Armitage test(e)	P = 0.9136			
Fisher Exact test(e)		P = 0.5000	P = 0.0559	P = 0.7525
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	5/50(10.0)	2/50(4.0)	6/50(12.0)	7/50(14.0)
Adjusted rates(b)	14.29	7.14	25.00	28.57
Terminal rates(c)	3/26(11.5)	1/26(3.8)	3/15(20.0)	4/14(28.6)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1443			
Prevalence method(d)	P = 0.0918			
Combined analysis(d)	P = 0.0508			
Cochran-Armitage test(e)	P = 0.2215			
Fisher Exact test(e)		P = 0.2180	P = 0.5000	P = 0.3798
	SITE : lymph node			
	TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	8/50(16.0)	7/50(14.0)	10/50(20.0)	3/50(6.0)
Adjusted rates(b)	19.23	19.23	26.67	7.14
Terminal rates(c)	5/26(19.2)	5/26(19.2)	4/15(26.7)	1/14(7.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4722			
Prevalence method(d)	P = 0.8540			
Combined analysis(d)	P = 0.7662			
Cochran-Armitage test(e)	P = 0.0970			
Fisher Exact test(e)		P = 0.5000	P = 0.3976	P = 0.0999

Group Name	Control	0.6ppm	2.5ppm	10ppm
SITE : stomach				
TUMOR : squamous cell papilloma				
Tumor rate				
Overall rates(a)	0/50(0.0)	1/50(2.0)	0/50(0.0)	3/50(6.0)
Adjusted rates(b)	0.0	3.13	0.0	17.65
Terminal rates(c)	0/26(0.0)	0/26(0.0)	0/15(0.0)	2/14(14.3)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0090**			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.0268*			
Fisher Exact test(e)		P = 0.5000	P = N.C.	P = 0.1212
SITE : liver				
TUMOR : hepatocellular adenoma				
Tumor rate				
Overall rates(a)	6/50(12.0)	10/50(20.0)	4/50(8.0)	2/50(4.0)
Adjusted rates(b)	22.22	26.92	18.75	6.67
Terminal rates(c)	5/26(19.2)	7/26(26.9)	2/15(13.3)	0/14(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.9526			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.0412*			
Fisher Exact test(e)		P = 0.2070	P = 0.3703	P = 0.1343
SITE : liver				
TUMOR : histiocytic sarcoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	3/50(6.0)	4/50(8.0)	2/50(4.0)
Adjusted rates(b)	0.0	7.69	6.67	0.0
Terminal rates(c)	0/26(0.0)	2/26(7.7)	1/15(6.7)	0/14(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1496			
Prevalence method(d)	P = 0.6426			
Combined analysis(d)	P = 0.2643			
Cochran-Armitage test(e)	P = 0.8425			
Fisher Exact test(e)		P = 0.1212	P = 0.0587	P = 0.2475

Group Name	Control	0.6ppm	2.5ppm	10ppm
SITE : liver				
TUMOR : hemangiosarcoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	2/50(4.0)	1/50(2.0)	3/50(6.0)
Adjusted rates(b)	0.0	3.45	0.0	7.14
Terminal rates(c)	0/26(0.0)	0/26(0.0)	0/15(0.0)	1/14(7.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2558			
Prevalence method(d)	P = 0.0724			
Combined analysis(d)	P = 0.0682			
Cochran-Armitage test(e)	P = 0.1445			
Fisher Exact test(e)		P = 0.2475	P = 0.5000	P = 0.1212
SITE : liver				
TUMOR : hepatocellular carcinoma				
Tumor rate				
Overall rates(a)	5/50(10.0)	5/50(10.0)	2/50(4.0)	6/50(12.0)
Adjusted rates(b)	15.38	14.29	11.76	14.29
Terminal rates(c)	4/26(15.4)	3/26(11.5)	1/15(6.7)	2/14(14.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0535			
Prevalence method(d)	P = 0.4242			
Combined analysis(d)	P = 0.1343			
Cochran-Armitage test(e)	P = 0.5753			
Fisher Exact test(e)		P = 0.6297	P = 0.2180	P = 0.5000
SITE : liver				
TUMOR : hemangioma,hemangiosarcoma				
Tumor rate				
Overall rates(a)	2/50(4.0)	4/50(8.0)	2/50(4.0)	4/50(8.0)
Adjusted rates(b)	6.45	8.82	3.45	12.50
Terminal rates(c)	1/26(3.8)	0/26(0.0)	0/15(0.0)	1/14(7.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2558			
Prevalence method(d)	P = 0.2361			
Combined analysis(d)	P = 0.1791			
Cochran-Armitage test(e)	P = 0.5456			
Fisher Exact test(e)		P = 0.3389	P = 0.6913	P = 0.3389

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : liver			
	TUMOR : hepatocellular adenoma, hepatocellular carcinoma			
Tumor rate				
Overall rates(a)	10/50(20.0)	14/50(28.0)	6/50(12.0)	8/50(16.0)
Adjusted rates(b)	33.33	35.71	29.41	20.00
Terminal rates(c)	8/26(30.8)	9/26(34.6)	3/15(20.0)	2/14(14.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0535			
Prevalence method(d)	P = 0.8597			
Combined analysis(d)	P = 0.5831			
Cochran-Armitage test(e)	P = 0.3417			
Fisher Exact test(e)		P = 0.2415	P = 0.2070	P = 0.3976
	SITE : epididymis			
	TUMOR : histiocytic sarcoma			
Tumor rate				
Overall rates(a)	2/50(4.0)	0/50(0.0)	3/50(6.0)	1/50(2.0)
Adjusted rates(b)	3.85	0.0	6.67	0.0
Terminal rates(c)	1/26(3.8)	0/26(0.0)	1/15(6.7)	0/14(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3212			
Prevalence method(d)	P = 0.5506			
Combined analysis(d)	P = 0.4287			
Cochran-Armitage test(e)	P = 0.8233			
Fisher Exact test(e)		P = 0.2475	P = 0.5000	P = 0.5000

Group Name	Control	0.6ppm	2.5ppm	10ppm
SITE : Harderian gland				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	5/50(10.0)	5/50(10.0)
Adjusted rates(b)	2.86	3.85	20.83	26.67
Terminal rates(c)	0/26(0.0)	1/26(3.8)	3/15(20.0)	3/14(21.4)
Statistical analysis				
Peto test				
Standard method(d)	P = -------			
Prevalence method(d)	P = 0.0174*			
Combined analysis(d)	P = -------			
Cochran-Armitage test(e)	P = 0.0758			
Fisher Exact test(e)		P = 0.7525	P = 0.1022	P = 0.1022

(HPT360A)

BAIS5

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------- : There is no data which should be statistical analysis.
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01
N.C. :Statistical value cannot be calculated and was not significant.

STUDY No. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : ALL SITE			
	TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	8/50(16.0)	7/50(14.0)	10/50(20.0)	3/50(6.0)
Adjusted rates(b)	19.23	19.23	26.67	7.14
Terminal rates(c)	5/26(19.2)	5/26(19.2)	4/15(26.7)	1/14(7.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4722			
Prevalence method(d)	P = 0.8540			
Combined analysis(d)	P = 0.7662			
Cochran-Armitage test(e)	P = 0.0970			
Fisher Exact test(e)		P = 0.5000	P = 0.3976	P = 0.0999

(HPT360A)

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------ : There is no data which should be statistical analysis.
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01
N.C. :Statistical value cannot be calculated and was not significant.

TABLE O2

NEOPLASTIC LESIONS-INCIDENCE

AND STATISTICAL ANALYSIS : FEMALE

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : nasal cavity			
	TUMOR : hemangioma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	3/50(6.0)	7/50(14.0)
Adjusted rates(b)	0.0	0.0	9.38	38.46
Terminal rates(c)	0/27(0.0)	0/15(0.0)	1/19(5.3)	3/ 9(33.3)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.0003**			
Fisher Exact test(e)		P = N.C.	P = 0.1212	P = 0.0062**
	SITE : nasal cavity			
	TUMOR : hemangiosarcoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	1/50(2.0)	4/50(8.0)
Adjusted rates(b)	0.0	0.0	4.17	10.53
Terminal rates(c)	0/27(0.0)	0/15(0.0)	0/19(0.0)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0146* ?			
Prevalence method(d)	P = 0.0253*			
Combined analysis(d)	P = 0.0011**			
Cochran-Armitage test(e)	P = 0.0030**			
Fisher Exact test(e)		P = N.C.	P = 0.5000	P = 0.0587
	SITE : nasal cavity			
	TUMOR : hemangioma,hemangiosarcoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	4/50(8.0)	11/50(22.0)
Adjusted rates(b)	0.0	0.0	12.50	40.00
Terminal rates(c)	0/27(0.0)	0/15(0.0)	1/19(5.3)	3/ 9(33.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0146* ?			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P < 0.0001**			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = 0.0587	P = 0.0003**

Group Name	Control	0.6ppm	2.5ppm	10ppm
SITE : nasal cavity				
TUMOR : hemangiosarcoma, adenocarcinoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	1/50(2.0)	5/50(10.0)
Adjusted rates(b)	0.0	0.0	4.17	15.79
Terminal rates(c)	0/27(0.0)	0/15(0.0)	0/19(0.0)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0146* ?			
Prevalence method(d)	P = 0.0037**			
Combined analysis(d)	P = 0.0001**			
Cochran-Armitage test(e)	P = 0.0006**			
Fisher Exact test(e)		P = N.C.	P = 0.5000	P = 0.0281*
SITE : nasal cavity				
TUMOR : hemangioma, hemangiosarcoma, adenocarcinoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	4/50(8.0)	12/50(24.0)
Adjusted rates(b)	0.0	0.0	12.50	46.67
Terminal rates(c)	0/27(0.0)	0/15(0.0)	1/19(5.3)	4/ 9(44.4)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0146* ?			
Prevalence method(d)	P < 0.0001**			
Combined analysis(d)	P < 0.0001**			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = 0.0587	P = 0.0001**
SITE : lung				
TUMOR : bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	0/50(0.0)	2/50(4.0)	0/50(0.0)	5/50(10.0)
Adjusted rates(b)	0.0	4.35	0.0	25.00
Terminal rates(c)	0/27(0.0)	0/15(0.0)	0/19(0.0)	2/ 9(22.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1240			
Prevalence method(d)	P = 0.0114*			
Combined analysis(d)	P = 0.0028**			
Cochran-Armitage test(e)	P = 0.0064**			
Fisher Exact test(e)		P = 0.2475	P = N.C.	P = 0.0281*

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	2/50(4.0)	4/50(8.0)	2/50(4.0)	5/50(10.0)
Adjusted rates(b)	6.45	13.33	10.53	25.00
Terminal rates(c)	1/27(3.7)	2/15(13.3)	2/19(10.5)	2/ 9(22.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1240			
Prevalence method(d)	P = 0.1378			
Combined analysis(d)	P = 0.0621			
Cochran-Armitage test(e)	P = 0.2867			
Fisher Exact test(e)		P = 0.3389	P = 0.6913	P = 0.2180
	SITE : lymph node			
	TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	18/50(36.0)	19/50(38.0)	19/50(38.0)	9/50(18.0)
Adjusted rates(b)	37.04	46.67	30.00	44.44
Terminal rates(c)	10/27(37.0)	7/15(46.7)	5/19(26.3)	4/ 9(44.4)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8142			
Prevalence method(d)	P = 0.4175			
Combined analysis(d)	P = 0.7502			
Cochran-Armitage test(e)	P = 0.0155*			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.0352*
	SITE : liver			
	TUMOR : histiocytic sarcoma			
Tumor rate				
Overall rates(a)	5/50(10.0)	5/50(10.0)	0/50(0.0)	5/50(10.0)
Adjusted rates(b)	5.13	5.26	0.0	0.0
Terminal rates(c)	1/27(3.7)	0/15(0.0)	0/19(0.0)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0918			
Prevalence method(d)	P = 0.9358			
Combined analysis(d)	P = 0.2414			
Cochran-Armitage test(e)	P = 0.7943			
Fisher Exact test(e)		P = 0.6297	P = 0.0281*	P = 0.6297

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : liver			
	TUMOR : hepatocellular carcinoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	1/50(2.0)	3/50(6.0)	1/50(2.0)
Adjusted rates(b)	0.0	6.67	7.32	0.0
Terminal rates(c)	0/27(0.0)	1/15(6.7)	1/19(5.3)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1035			
Prevalence method(d)	P = 0.6767			
Combined analysis(d)	P = 0.3371			
Cochran-Armitage test(e)	P = 0.8448			
Fisher Exact test(e)		P = 0.5000	P = 0.1212	P = 0.5000
	SITE : liver			
	TUMOR : hepatocellular adenoma,hepatocellular carcinoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	2/50(4.0)	3/50(6.0)	1/50(2.0)
Adjusted rates(b)	3.70	13.33	7.32	0.0
Terminal rates(c)	1/27(3.7)	2/15(13.3)	1/19(5.3)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1035			
Prevalence method(d)	P = 0.8120			
Combined analysis(d)	P = 0.4941			
Cochran-Armitage test(e)	P = 0.6838			
Fisher Exact test(e)		P = 0.5000	P = 0.3087	P = 0.7525
	SITE : pituitary gland			
	TUMOR : adenoma			
Tumor rate				
Overall rates(a)	4/50(8.0)	10/50(20.0)	9/50(18.0)	7/50(14.0)
Adjusted rates(b)	10.00	50.00	31.58	33.33
Terminal rates(c)	1/27(3.7)	7/15(46.7)	6/19(31.6)	3/ 9(33.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1092			
Prevalence method(d)	P = 0.3242			
Combined analysis(d)	P = 0.2041			
Cochran-Armitage test(e)	P = 0.9901			
Fisher Exact test(e)		P = 0.0739	P = 0.1168	P = 0.2623

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : ovary			
	TUMOR : cystadenoma			
Tumor rate				
Overall rates(a)	4/50(8.0)	4/50(8.0)	0/50(0.0)	2/50(4.0)
Adjusted rates(b)	11.11	21.05	0.0	11.11
Terminal rates(c)	3/27(11.1)	3/15(20.0)	0/19(0.0)	1/ 9(11.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.6292			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.4001			
Fisher Exact test(e)		P = 0.6425	P = 0.0587	P = 0.3389
	SITE : uterus			
	TUMOR : endometrial stromal polyp			
Tumor rate				
Overall rates(a)	3/50(6.0)	3/50(6.0)	2/50(4.0)	2/50(4.0)
Adjusted rates(b)	11.11	13.33	10.53	9.09
Terminal rates(c)	3/27(11.1)	2/15(13.3)	2/19(10.5)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.4803			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.6286			
Fisher Exact test(e)		P = 0.6611	P = 0.5000	P = 0.5000
	SITE : uterus			
	TUMOR : histiocytic sarcoma			
Tumor rate				
Overall rates(a)	11/50(22.0)	10/50(20.0)	12/50(24.0)	18/50(36.0)
Adjusted rates(b)	9.38	13.33	26.32	23.08
Terminal rates(c)	1/27(3.7)	2/15(13.3)	5/19(26.3)	2/ 9(22.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0400*			
Prevalence method(d)	P = 0.0394*			
Combined analysis(d)	P = 0.0079**			
Cochran-Armitage test(e)	P = 0.0465*			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.0928

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : Harderian gland			
	TUMOR : adenoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	2/50(4.0)	4/50(8.0)
Adjusted rates(b)	3.70	3.45	5.26	15.79
Terminal rates(c)	1/27(3.7)	0/15(0.0)	1/19(5.3)	0/ 9(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -------			
Prevalence method(d)	P = 0.0377*			
Combined analysis(d)	P = -------			
Cochran-Armitage test(e)	P = 0.0794			
Fisher Exact test(e)		P = 0.7525	P = 0.5000	P = 0.1811

(HPT360A)

BAIS5

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------- : There is no data which should be statistical analysis.
Significant difference ; * : $P \leqq 0.05$ ** : $P \leqq 0.01$
N.C. :Statistical value cannot be calculated and was not significant.

Group Name	Control	0.6ppm	2.5ppm	10ppm
	SITE : ALL SITE			
	TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	18/50(36.0)	19/50(38.0)	20/50(40.0)	9/50(18.0)
Adjusted rates(b)	37.04	46.67	35.00	44.44
Terminal rates(c)	10/27(37.0)	7/15(46.7)	6/19(31.6)	4/ 9(44.4)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8142			
Prevalence method(d)	P = 0.4073			
Combined analysis(d)	P = 0.7449			
Cochran-Armitage test(e)	P = 0.0147*			
Fisher Exact test(e)		P = 0.5000	P = 0.4185	P = 0.0352*

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------ : There is no data which should be statistical analysis.
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01
N.C. :Statistical value cannot be calculated and was not significant.

TABLE P1

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR :

MALE

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Integumentary system/appandage}						
subcutis			<50>	<50>	<50>	<50>
	metastasis:liver tumor		0	0	1	0
	metastasis:epididymis tumor		0	0	1	1
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	metastasis:liver tumor		0	0	0	1
	metastasis:subcutis tumor		0	1	1	0
	metastasis:peripheral nerve tumor		0	0	0	1
	metastasis:epididymis tumor		0	0	1	0
lung			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	2	2	1
	metastasis:liver tumor		1	1	1	2
	metastasis:subcutis tumor		1	1	1	2
	metastasis:urinary bladder tumor		0	0	0	1
	metastasis:epididymis tumor		1	0	2	1
	metastasis:kidney tumor		0	0	1	0
	metastasis:mediastinum tum		0	0	0	1
{Hematopoietic system}						
bone marrow			<50>	<50>	<50>	<50>
	leukemic cell infiltration		5	2	3	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	0.6ppm	2.5ppm	10ppm
			50	50	50	50
{Hematopoietic system}						
bone marrow			<50>	<50>	<50>	<50>
	metastasis:subcutis tumor		0	1	1	0
	metastasis:spleen tumor		0	1	0	0
	metastasis:urinary bladder tumor		0	0	0	1
	metastasis:epididymis tumor		1	0	1	1
lymph node			<50>	<50>	<50>	<50>
	metastasis:liver tumor		0	0	0	1
	metastasis:spleen tumor		0	1	0	0
	metastasis:urinary bladder tumor		0	0	0	1
	metastasis:salivary gland tumor		0	1	0	0
spleen			<50>	<50>	<50>	<50>
	leukemic cell infiltration		5	2	7	2
	metastasis:liver tumor		0	1	0	0
	metastasis:subcutis tumor		0	0	0	1
	metastasis:salivary gland tumor		0	1	0	0
	metastasis:lymph node tumor		0	1	1	0
{Digestive system}						
tongue			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	0
salivary gl			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Digestive system}						
stomach			<50>	<50>	<50>	<50>
	metastasis:liver tumor		0	0	1	0
	metastasis:epididymis tumor		1	0	0	0
	metastasis:lymph node tumor		0	1	0	0
small intes			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	2	2	1
	metastasis:liver tumor		0	0	1	0
	metastasis:epididymis tumor		1	0	0	0
large intes			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
liver			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	1	1
	metastasis:subcutis tumor		0	2	1	0
	metastasis:urinary bladder tumor		0	0	0	1
	metastasis:epididymis tumor		1	0	2	1
	metastasis:salivary gland tumor		1	1	0	0
	metastasis:mediastinum tumor		0	0	0	1
	metastasis:lymph node tumor		0	1	0	0
pancreas			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	1	0
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	1	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	metastasis:lung tumor		0	0	0	1
	metastasis:urinary bladder tumor		0	0	0	1
	metastasis:lymph node tumor		0	2	0	0
urin bladd			<50>	<50>	<50>	<50>
	metastasis:epididymis tumor		0	0	0	1
urethra			<50>	<50>	<50>	<50>
	metastasis:epididymis tumor		0	0	1	0
{Endocrine system}						
pituitary			<49>	<50>	<50>	<50>
	metastasis:peripheral nerve tumor		0	0	0	1
adrenal			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	1	1	1
	metastasis:subcutis tumor		0	1	0	0
	metastasis:epididymis tumor		1	0	0	0
{Reproductive system}						
testis			<50>	<50>	<50>	<50>
	metastasis:epididymis tumor		0	0	1	0
epididymis			<50>	<50>	<50>	<50>
	metastasis:subcutis tumor		0	1	0	0
prostate			<50>	<50>	<50>	<50>
	metastasis:urinary bladder tumor		0	0	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Reproductive system}						
prostate			<50>	<50>	<50>	<50>
	metastasis:epididymis tumor		0	0	0	1
{Nervous system}						
brain			<50>	<50>	<50>	<50>
	metastasis:liver tumor		0	0	0	1
{Musculoskeletal system}						
bone			<50>	<50>	<50>	<50>
	metastasis:bone marrow tumor		0	0	0	1
{Body cavities}						
pleura			<50>	<50>	<50>	<50>
	metastasis:subcutis tumor		0	0	1	0
	metastasis:lung tumor		0	0	0	1
mediastinum			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	1	0
	metastasis:salivary gland tumor		0	1	0	0
peritoneum			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
	metastasis:liver tumor		0	1	0	1
	metastasis:subcutis tumor		0	1	0	1
	metastasis:epididymis tumor		1	0	0	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	0.6ppm	2.5ppm	10ppm
		No. of Animals on Study	50	50	50	50
{Body cavities}						
peritoneum			<50>	<50>	<50>	<50>
	metastasis:kidney tumor		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

TABLE P2

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR :

FEMALE

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Integumentary system/appandage}						
skin/app			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	0	2
	metastasis:peritoneum tumor		0	0	0	1
subcutis			<50>	<50>	<50>	<50>
	metastasis:bone tumor		0	1	0	1
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	2	1	1
	metastasis:uterus tumor		1	0	0	0
	metastasis:subcutis tumor		0	1	0	0
larynx			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	0	0
trachea			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	0	0
lung			<50>	<50>	<50>	<50>
	leukemic cell infiltration		11	8	13	5
	metastasis:liver tumor		2	2	0	2
	metastasis:uterus tumor		2	4	7	7
	metastasis:peritoneum tumor		0	0	1	0
	metastasis:subcutis tumor		0	3	2	1
	metastasis:bone tumor		0	1	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Hematopoietic system}						
bone marrow			<50>	<50>	<50>	<50>
	leukemic cell infiltration		14	19	18	7
	metastasis:liver tumor		4	4	0	5
	metastasis:uterus tumor		8	9	9	16
	metastasis:peritoneum tumor		0	0	1	0
	metastasis:subcutis tumor		0	1	0	3
	metastasis:lymph node tumor		1	0	0	1
lymph node			<50>	<50>	<50>	<50>
	metastasis:liver tumor		0	1	0	0
	metastasis:uterus tumor		1	2	2	5
	metastasis:peritoneum tumor		0	0	1	0
	metastasis:subcutis tumor		0	1	1	1
	metastasis:bone tumor		0	0	0	1
	metastasis:retroperitoneum tumor		0	0	0	1
spleen			<50>	<50>	<50>	<50>
	leukemic cell infiltration		15	17	14	6
	metastasis:liver tumor		2	2	0	2
	metastasis:uterus tumor		0	0	0	1
	metastasis:peritoneum tumor		0	0	1	0
	metastasis:subcutis tumor		0	0	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Hematopoietic system}						
spleen			<50>	<50>	<50>	<50>
	metastasis:lymph node tumor		2	0	0	1
{Circulatory system}						
heart			<50>	<50>	<50>	<50>
	leukemic cell infiltration		3	4	2	0
	metastasis:uterus tumor		1	0	0	0
{Digestive system}						
tongue			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	2	1	1
	metastasis:peritoneum tumor		0	0	1	0
salivary gl			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	3	2
	metastasis:subcutis tumor		0	0	1	0
stomach			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	3	5	1
	metastasis:liver tumor		1	0	0	1
	metastasis:uterus tumor		0	1	1	0
small intes			<50>	<50>	<50>	<50>
	leukemic cell infiltration		3	8	5	3
	metastasis:liver tumor		0	0	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Digestive system}						
small intes			<50>	<50>	<50>	<50>
	metastasis:uterus tumor		2	1	2	0
	metastasis:retroperitoneum tumor		0	0	0	1
large intes			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	2	1	0
	metastasis:uterus tumor		0	1	1	0
liver			<50>	<50>	<50>	<50>
	leukemic cell infiltration		7	9	11	4
	metastasis:uterus tumor		10	7	9	13
	metastasis:peritoneum tumor		0	0	1	0
	metastasis:subcutis tumor		0	3	1	2
	metastasis:spleen tumor		0	0	0	1
	metastasis:lymph node tumor		2	0	0	1
gall bladd			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	0
pancreas			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	3	3
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	leukemic cell infiltration		9	9	9	4
	metastasis:liver tumor		1	0	0	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	metastasis:uterus tumor		2	4	4	5
	metastasis:peritoneum tumor		0	0	1	0
urin bladd			<50>	<50>	<50>	<50>
	leukemic cell infiltration		3	3	4	1
{Endocrine system}						
pituitary			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	2	0
thyroid			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	0	0
adrenal			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	2	1
	metastasis:liver tumor		1	0	0	0
	metastasis:uterus tumor		0	0	3	1
{Reproductive system}						
ovary			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	2	8	0
	metastasis:liver tumor		1	0	0	1
	metastasis:uterus tumor		3	6	6	8
	metastasis:subcutis tumor		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.6ppm 50	2.5ppm 50	10ppm 50
{Reproductive system}						
uterus			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	3	0	0
	metastasis:subcutis tumor		0	0	0	2
vagina			<50>	<50>	<50>	<50>
	metastasis:uterus tumor		1	0	0	1
	metastasis:subcutis tumor		0	0	0	1
{Nervous system}						
brain			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	3	0	0
	metastasis:liver tumor		0	0	0	1
	metastasis:uterus tumor		0	1	0	1
	metastasis:subcutis tumor		0	1	0	0
spinal cord			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	0	1
{Special sense organs/appendage}						
Harder gl			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	2	3
	metastasis:liver tumor		0	0	0	1
	metastasis:peritoneum tumor		0	0	1	0
{Musculoskeletal system}						
muscle			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	2	2	2

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	0.6ppm	2.5ppm	10ppm
			50	50	50	50
{Musculoskeletal system}						
muscle			<50>	<50>	<50>	<50>
	metastasis:subcutis tumor		0	1	0	1
{Body cavities}						
pleura			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
	metastasis:subcutis tumor		0	1	0	0
mediastinum			<50>	<50>	<50>	<50>
	leukemic cell infiltration		8	5	4	0
peritoneum			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	4	3	1
	metastasis:uterus tumor		1	2	2	1
	metastasis:subcutis tumor		0	1	0	0
	metastasis:retroperitoneum tumor		0	0	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

TABLE Q1

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : B6D2F1/Crlj MALE MICE

TABLE Q1 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : B6D2F1/Crlj MALE MICE

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. - Max. (%)
Nasal cavity	2545			
Hemangioma 1)		0	0.0	0 - 0
Hemangiosarcoma 2)		1	0.0	0 - 2
1) + 2)		1	0.0	0 - 2
Adenoma		2	0.1	0 - 2
Lung	2544			
Bronchiolar-alveolar adenoma		221	8.7	2 - 18
Stomach	2545			
Squamous cell papilloma		7	0.3	0 - 2
Harderian gland	2543			
Adenoma		118	4.6	0 - 10

51 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No. : 0044, 0060, 0062, 0064, 0066, 0068, 0096, 0105, 0116, 0140, 0159, 0163, 0190, 0206, 0211, 0225, 0243, 0268, 0270, 0279, 0285, 0297, 0319, 0329, 0343, 0348, 0366, 0372, 0402, 0406, 0418, 0422, 0438, 0449, 0458, 0462, 0498, 0515, 0561, 0580, 0611, 0613, 0642, 0676, 0685, 0705, 0712, 0732, 0740, 0754, 0775

TABLE Q2

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : B6D2F1/Crlj FEMALE MICE

TABLE Q2 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : B6D2F1/Crlj FEMALE MICE

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. - Max. (%)
Nasal cavity	2547			
Hemangioma 1)		1	0.0	0 - 2
Hemangiosarcoma 2)		0	0.0	0 - 0
1) + 2)		1	0.0	0 - 2
Adenocarcinoma		0	0.0	0 - 0
Lung	2547			
Bronchiolar-alveolar carcinoma		68	2.7	0 - 8
Uterus	2545			
Histiocytic sarcoma		534	21.0	10 - 34
Harderian gland	2547			
Adenoma		80	3.1	0 - 12

51 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No. : 0044, 0060, 0062, 0064, 0066, 0068, 0096, 0105, 0116, 0140, 0159, 0163, 0190, 0206, 0211, 0225, 0243, 0268, 0270, 0279, 0285, 0297, 0319, 0329, 0343, 0348, 0366, 0372, 0402, 0406, 0418, 0422, 0438, 0449, 0458, 0462, 0498, 0515, 0561, 0580, 0611, 0613, 0642, 0676, 0685, 0705, 0712, 0732, 0740, 0754, 0775

TABLE R1

CAUSE OF DEATH : MALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
SEX : MALE

COUSE OF DEATH (SUMMARY)
(0-105W)

Group Name	Control	0.6ppm	2.5ppm	10ppm
Number of Dead and Moribund Animal	24	24	35	36
no microscop confirm	1	1	1	0
cardiovascular les	0	1	0	0
hepatic lesion	0	1	0	0
renal lesion	3	1	2	1
circulatory disor	0	0	1	0
urinary retention	0	3	5	0
amyloidosis	9	6	6	9
hydronephrosis	3	1	3	1
tumor d:leukemia	3	2	5	2
tumor d:subcutis	2	2	1	2
tumor d:nasal cavit	0	0	1	8
tumor d:lung	0	0	1	1
tumor d:lymph node	0	1	1	0
tumor d:spleen	0	2	1	2
tumor d:liver	1	3	4	5
tumor d:kidney	0	0	1	0
tumor d:urin bladd	0	0	0	2
tumor d:epididymis	1	0	2	1
tumor d:periph nerv	0	0	0	1
tumor d:mediastinum	1	0	0	1

TABLE R2

CAUSE OF DEATH : FEMALE

STUDY NO. : 0795
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
SEX : FEMALE

COUSE OF DEATH (SUMMARY)
(0-105W)

Group Name	Control	0.6ppm	2.5ppm	10ppm
Number of Dead and Moribund Animal	23	35	31	41
renal lesion	1	2	5	3
amyloidosis	0	5	1	1
hydronephrosis	1	0	0	2
tumor d:leukemia	8	12	13	5
tumor d:skin/app	0	0	1	0
tumor d:subcutis	1	4	2	4
tumor d:nasal cavit	0	0	0	2
tumor d:lung	0	0	0	1
tumor d:lymph node	1	0	0	1
tumor d:salivary gl	0	0	0	1
tumor d:liver	3	4	0	6
tumor d:pituitary	0	0	1	1
tumor d:uterus	8	7	7	12
tumor d:bone	0	1	0	0
tumor d:peritoneum	0	0	1	1
tumor d:retroperit	0	0	0	1